{
  "schema": "diognosis.reference-facts.v1",
  "generatedAt": "2026-07-11T05:35:41.222Z",
  "lastmod": "2026-07-11",
  "source": "Generated from the committed Diognosis app runtime and data/medication-class-guides.json validated examples.",
  "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
  "factCount": 85,
  "sourceLinkedFacts": 79,
  "provenanceClassifiedFacts": 85,
  "sourceIntegratedFacts": 79,
  "facts": [
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-simvastatin-clarithromycin",
      "label": "Simvastatin + clarithromycin",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "simvastatin",
          "name": "Simvastatin",
          "id": "simvastatin",
          "class": "Statin"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Simvastatin exposure may rise with Clarithromycin",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Simvastatin exposure may rise with Clarithromycin",
      "mechanismSummary": "Clarithromycin may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Simvastatin, Clarithromycin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 8 sources",
      "evidenceStatus": "fda label · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_simvastatin_label_cyp3a4",
        "ev_statin_cyp3a4_williams2002",
        "ev_simvastatin_multigene_choi2016",
        "ev_statin_slco1b1_abcg2_cpic2022"
      ],
      "evidenceSources": [
        {
          "ref": "ev_simvastatin_label_cyp3a4",
          "title": "Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_statin_cyp3a4_williams2002",
          "title": "Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors",
          "type": "clinical_pk",
          "pmid": "12036392",
          "doi": "10.2165/00003088-200241050-00003",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12036392/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_multigene_choi2016",
          "title": "Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid",
          "type": "rct",
          "pmid": "26367500",
          "doi": "10.1097/fpc.0000000000000176",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26367500/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_statin_slco1b1_abcg2_cpic2022",
          "title": "CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
          "type": "guideline",
          "pmid": "35152405",
          "doi": "10.1002/cpt.2557",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://pubmed.ncbi.nlm.nih.gov/12036392/",
        "https://pubmed.ncbi.nlm.nih.gov/26367500/",
        "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=simvastatin,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-simvastatin-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "simvastatin-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-simvastatin-itraconazole",
      "label": "Simvastatin + itraconazole",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "simvastatin",
          "name": "Simvastatin",
          "id": "simvastatin",
          "class": "Statin"
        },
        {
          "input": "itraconazole",
          "name": "Itraconazole",
          "id": "itraconazole",
          "class": "Azole Antifungal"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Simvastatin exposure may rise with Itraconazole",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Simvastatin exposure may rise with Itraconazole",
      "mechanismSummary": "Itraconazole may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Itraconazole inhibitor, current stack substrate burden. Affects Simvastatin, Itraconazole.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 8 sources",
      "evidenceStatus": "fda label · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_simvastatin_label_cyp3a4",
        "ev_statin_cyp3a4_williams2002",
        "ev_simvastatin_multigene_choi2016",
        "ev_statin_slco1b1_abcg2_cpic2022"
      ],
      "evidenceSources": [
        {
          "ref": "ev_simvastatin_label_cyp3a4",
          "title": "Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_statin_cyp3a4_williams2002",
          "title": "Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors",
          "type": "clinical_pk",
          "pmid": "12036392",
          "doi": "10.2165/00003088-200241050-00003",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12036392/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_multigene_choi2016",
          "title": "Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid",
          "type": "rct",
          "pmid": "26367500",
          "doi": "10.1097/fpc.0000000000000176",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26367500/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_statin_slco1b1_abcg2_cpic2022",
          "title": "CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
          "type": "guideline",
          "pmid": "35152405",
          "doi": "10.1002/cpt.2557",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://pubmed.ncbi.nlm.nih.gov/12036392/",
        "https://pubmed.ncbi.nlm.nih.gov/26367500/",
        "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=simvastatin,itraconazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-simvastatin-itraconazole",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "simvastatin-itraconazole",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-simvastatin-gemfibrozil",
      "label": "Simvastatin + gemfibrozil",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "simvastatin",
          "name": "Simvastatin",
          "id": "simvastatin",
          "class": "Statin"
        },
        {
          "input": "gemfibrozil",
          "name": "Gemfibrozil",
          "id": "gemfibrozil",
          "class": "Fibrate"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Simvastatin exposure may rise with Gemfibrozil",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Simvastatin exposure may rise with Gemfibrozil",
      "mechanismSummary": "Gemfibrozil may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Gemfibrozil inhibits OATP1B1 and CYP2C8, raising simvastatin acid exposure about 10-fold",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 4 sources",
      "evidenceStatus": "fda label · 4 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_statin_gemfibrozil_schneck2004",
        "ev_simvastatin_label_cyp3a4"
      ],
      "evidenceSources": [
        {
          "ref": "ev_statin_gemfibrozil_schneck2004",
          "title": "The effect of gemfibrozil on the pharmacokinetics of rosuvastatin",
          "type": "clinical_pk",
          "pmid": "15116058",
          "doi": "10.1016/j.clpt.2003.12.014",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15116058/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_label_cyp3a4",
          "title": "Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/15116058/",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 4 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=simvastatin,gemfibrozil&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-simvastatin-gemfibrozil",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "simvastatin-gemfibrozil",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-atorvastatin-clarithromycin",
      "label": "Atorvastatin + clarithromycin",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "atorvastatin",
          "name": "Atorvastatin",
          "id": "atorvastatin",
          "class": "Statin"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Atorvastatin exposure may rise with Clarithromycin",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Atorvastatin exposure may rise with Clarithromycin",
      "mechanismSummary": "Clarithromycin may increase Atorvastatin exposure, raising Atorvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Atorvastatin, Clarithromycin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 5 sources",
      "evidenceStatus": "guideline · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_statin_slco1b1_abcg2_cpic2022"
      ],
      "evidenceSources": [
        {
          "ref": "ev_statin_slco1b1_abcg2_cpic2022",
          "title": "CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
          "type": "guideline",
          "pmid": "35152405",
          "doi": "10.1002/cpt.2557",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=atorvastatin,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-atorvastatin-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "atorvastatin-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-rosuvastatin-gemfibrozil",
      "label": "Rosuvastatin + gemfibrozil",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "rosuvastatin",
          "name": "Rosuvastatin",
          "id": "rosuvastatin",
          "class": "Statin"
        },
        {
          "input": "gemfibrozil",
          "name": "Gemfibrozil",
          "id": "gemfibrozil",
          "class": "Fibrate"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Rosuvastatin exposure may rise with Gemfibrozil",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Rosuvastatin exposure may rise with Gemfibrozil",
      "mechanismSummary": "Gemfibrozil may increase Rosuvastatin exposure, raising Rosuvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Gemfibrozil inhibits OATP1B1, raising rosuvastatin exposure about 2-fold",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_statin_gemfibrozil_schneck2004",
        "ev_rosuvastatin_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_statin_gemfibrozil_schneck2004",
          "title": "The effect of gemfibrozil on the pharmacokinetics of rosuvastatin",
          "type": "clinical_pk",
          "pmid": "15116058",
          "doi": "10.1016/j.clpt.2003.12.014",
          "url": "https://pubmed.ncbi.nlm.nih.gov/15116058/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_rosuvastatin_label",
          "title": "Rosuvastatin (Crestor) Prescribing Information — OATP1B1/BCRP inhibitor interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/15116058/",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=rosuvastatin,gemfibrozil&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-rosuvastatin-gemfibrozil",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "rosuvastatin-gemfibrozil",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-nirmatrelvir-ritonavir-simvastatin",
      "label": "Nirmatrelvir/ritonavir + simvastatin",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "nirmatrelvir_ritonavir",
          "name": "Nirmatrelvir/Ritonavir",
          "id": "nirmatrelvir_ritonavir",
          "class": "COVID-19 Antiviral / CYP3A Booster"
        },
        {
          "input": "simvastatin",
          "name": "Simvastatin",
          "id": "simvastatin",
          "class": "Statin"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Simvastatin exposure may rise with Nirmatrelvir/Ritonavir",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Simvastatin exposure may rise with Nirmatrelvir/Ritonavir",
      "mechanismSummary": "Nirmatrelvir/Ritonavir may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Nirmatrelvir/Ritonavir inhibitor, current stack substrate burden. Affects Nirmatrelvir/Ritonavir, Simvasta...",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 8 sources",
      "evidenceStatus": "fda label · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_paxlovid_cyp3a_label",
        "ev_simvastatin_multigene_choi2016",
        "ev_simvastatin_label_cyp3a4",
        "ev_statin_slco1b1_abcg2_cpic2022"
      ],
      "evidenceSources": [
        {
          "ref": "ev_paxlovid_cyp3a_label",
          "title": "Paxlovid prescribing information - CYP3A inhibition and strong inducer contraindications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_multigene_choi2016",
          "title": "Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid",
          "type": "rct",
          "pmid": "26367500",
          "doi": "10.1097/fpc.0000000000000176",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26367500/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_label_cyp3a4",
          "title": "Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_statin_slco1b1_abcg2_cpic2022",
          "title": "CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
          "type": "guideline",
          "pmid": "35152405",
          "doi": "10.1002/cpt.2557",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a",
        "https://pubmed.ncbi.nlm.nih.gov/26367500/",
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=nirmatrelvir_ritonavir,simvastatin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-nirmatrelvir-ritonavir-simvastatin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "nirmatrelvir-ritonavir-simvastatin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-darolutamide-rosuvastatin",
      "label": "Darolutamide + rosuvastatin",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "darolutamide",
          "name": "Darolutamide",
          "id": "darolutamide",
          "class": "Androgen Receptor Inhibitor / Oncology"
        },
        {
          "input": "rosuvastatin",
          "name": "Rosuvastatin",
          "id": "rosuvastatin",
          "class": "Statin"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Darolutamide exposure may rise with Rosuvastatin",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Darolutamide exposure may rise with Rosuvastatin",
      "mechanismSummary": "Rosuvastatin may increase Darolutamide exposure, raising Darolutamide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Darolutamide inhibits BCRP/OATP transport and can markedly raise rosuvastatin exposure.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_darolutamide_bcrp_label",
        "ev_rosuvastatin_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_darolutamide_bcrp_label",
          "title": "Darolutamide prescribing information - BCRP/OATP inhibition and rosuvastatin exposure",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_rosuvastatin_label",
          "title": "Rosuvastatin (Crestor) Prescribing Information — OATP1B1/BCRP inhibitor interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=darolutamide,rosuvastatin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-darolutamide-rosuvastatin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "darolutamide-rosuvastatin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "statins-lipids-leflunomide-rosuvastatin",
      "label": "Leflunomide + rosuvastatin",
      "guideId": "statins-lipids",
      "guideTitle": "Statins and Lipid Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "leflunomide",
          "name": "Leflunomide",
          "id": "leflunomide",
          "class": "DMARD / Pyrimidine Synthesis Inhibitor Prodrug"
        },
        {
          "input": "rosuvastatin",
          "name": "Rosuvastatin",
          "id": "rosuvastatin",
          "class": "Statin"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Rosuvastatin exposure may rise with Leflunomide",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Rosuvastatin exposure may rise with Leflunomide",
      "mechanismSummary": "Leflunomide may increase Rosuvastatin exposure, raising Rosuvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Active metabolite teriflunomide inhibits BCRP/OATP transporters and can raise rosuvastatin exposure.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_leflunomide_teriflunomide_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_leflunomide_teriflunomide_label",
          "title": "Leflunomide prescribing information - active teriflunomide metabolite, washout, and transporter interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91712aad-d96c-4ef0-97e7-b31ed18ca6d8",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91712aad-d96c-4ef0-97e7-b31ed18ca6d8"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=leflunomide,rosuvastatin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#statins-lipids-leflunomide-rosuvastatin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "leflunomide-rosuvastatin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-potassium-chloride-spironolactone",
      "label": "Potassium chloride + spironolactone",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "potassium_chloride",
          "name": "Potassium Chloride",
          "id": "potassium_chloride",
          "class": "Electrolyte Supplement / Potassium"
        },
        {
          "input": "spironolactone",
          "name": "Spironolactone",
          "id": "spironolactone",
          "class": "K-sparing Diuretic"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "High potassium risk may increase",
      "reviewQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "patientSummary": "High potassium risk may increase",
      "patientQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "clinicianSummary": "High potassium risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Potassium supplementation plus aldosterone antagonism reduces potassium excretion reserve.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_potassium_hyperkalemia_label",
        "ev_spironolactone_tmpsmx_antoniou2011"
      ],
      "evidenceSources": [
        {
          "ref": "ev_potassium_hyperkalemia_label",
          "title": "Potassium chloride prescribing information - hyperkalemia risk with potassium-retaining medicines",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=potassium%20chloride",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_spironolactone_tmpsmx_antoniou2011",
          "title": "Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study",
          "type": "observational",
          "pmid": "21911446",
          "doi": "10.1136/bmj.d5228",
          "url": "https://pubmed.ncbi.nlm.nih.gov/21911446/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=potassium%20chloride",
        "https://pubmed.ncbi.nlm.nih.gov/21911446/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=potassium_chloride,spironolactone&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-potassium-chloride-spironolactone",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "potassium-chloride-spironolactone",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-potassium-chloride-lisinopril",
      "label": "Potassium chloride + lisinopril",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "potassium_chloride",
          "name": "Potassium Chloride",
          "id": "potassium_chloride",
          "class": "Electrolyte Supplement / Potassium"
        },
        {
          "input": "lisinopril",
          "name": "Lisinopril",
          "id": "lisinopril",
          "class": "ACE Inhibitor"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "High potassium risk may increase",
      "reviewQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "patientSummary": "High potassium risk may increase",
      "patientQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "clinicianSummary": "High potassium risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "ACE inhibition lowers aldosterone-mediated potassium excretion while supplementation increases potassium load.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_potassium_hyperkalemia_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_potassium_hyperkalemia_label",
          "title": "Potassium chloride prescribing information - hyperkalemia risk with potassium-retaining medicines",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=potassium%20chloride",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=potassium%20chloride"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=potassium_chloride,lisinopril&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-potassium-chloride-lisinopril",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "potassium-chloride-lisinopril",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-spironolactone-tmp-smx",
      "label": "Spironolactone + TMP-SMX",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "spironolactone",
          "name": "Spironolactone",
          "id": "spironolactone",
          "class": "K-sparing Diuretic"
        },
        {
          "input": "trimethoprim_sulfamethoxazole",
          "name": "Trimethoprim/Sulfamethoxazole",
          "id": "trimethoprim_sulfamethoxazole",
          "class": "Sulfonamide Antibiotic / Folate Antagonist"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "High potassium risk may increase",
      "reviewQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "patientSummary": "High potassium risk may increase",
      "patientQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "clinicianSummary": "High potassium risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Both block potassium excretion via different mechanisms",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "primary-literature linked · observational · 1 source",
      "evidenceStatus": "observational · 1 source · mechanistic moderate · primary-literature linked",
      "evidenceRefs": [
        "ev_spironolactone_tmpsmx_antoniou2011"
      ],
      "evidenceSources": [
        {
          "ref": "ev_spironolactone_tmpsmx_antoniou2011",
          "title": "Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study",
          "type": "observational",
          "pmid": "21911446",
          "doi": "10.1136/bmj.d5228",
          "url": "https://pubmed.ncbi.nlm.nih.gov/21911446/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/21911446/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · observational · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=spironolactone,trimethoprim_sulfamethoxazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-spironolactone-tmp-smx",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "spironolactone-tmp-smx",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-sacubitril-valsartan-lisinopril",
      "label": "Sacubitril/valsartan + lisinopril",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "sacubitril_valsartan",
          "name": "Sacubitril/Valsartan",
          "id": "sacubitril_valsartan",
          "class": "ARNI / ARB / Neprilysin Inhibitor"
        },
        {
          "input": "lisinopril",
          "name": "Lisinopril",
          "id": "lisinopril",
          "class": "ACE Inhibitor"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "High potassium risk may increase",
      "reviewQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "patientSummary": "High potassium risk may increase",
      "patientQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "clinicianSummary": "High potassium risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Sacubitril/neprilysin inhibition plus ACE inhibition increases bradykinin-mediated angioedema risk.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_sacubitril_valsartan_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_sacubitril_valsartan_label",
          "title": "Sacubitril/valsartan prescribing information - ACE inhibitor contraindication and potassium risk",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=sacubitril_valsartan,lisinopril&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-sacubitril-valsartan-lisinopril",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "sacubitril-valsartan-lisinopril",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-nitroglycerin-sildenafil",
      "label": "Nitroglycerin + sildenafil",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "nitroglycerin",
          "name": "Nitroglycerin",
          "id": "nitroglycerin",
          "class": "Nitrate Antianginal"
        },
        {
          "input": "sildenafil",
          "name": "Sildenafil",
          "id": "sildenafil",
          "class": "PDE5 Inhibitor"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Low blood pressure risk may increase",
      "reviewQuestion": "Can you check whether this combination could cause low blood pressure, dizziness, or fainting?",
      "patientSummary": "Low blood pressure risk may increase",
      "patientQuestion": "Can you check whether this combination could cause low blood pressure, dizziness, or fainting?",
      "clinicianSummary": "Low blood pressure risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Both increase cGMP-mediated vasodilation; PDE5 inhibition amplifies nitrate hypotensive effects.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_nitrate_pde5_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_nitrate_pde5_label",
          "title": "Nitrate prescribing information - PDE5 inhibitor contraindication",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=nitroglycerin,sildenafil&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-nitroglycerin-sildenafil",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "nitroglycerin-sildenafil",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-sildenafil-tamsulosin",
      "label": "Sildenafil + tamsulosin",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "sildenafil",
          "name": "Sildenafil",
          "id": "sildenafil",
          "class": "PDE5 Inhibitor"
        },
        {
          "input": "tamsulosin",
          "name": "Tamsulosin",
          "id": "tamsulosin",
          "class": "Alpha-blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Low blood pressure risk may increase",
      "reviewQuestion": "Can you check whether this combination could cause low blood pressure, dizziness, or fainting?",
      "patientSummary": "Low blood pressure risk may increase",
      "patientQuestion": "Can you check whether this combination could cause low blood pressure, dizziness, or fainting?",
      "clinicianSummary": "Low blood pressure risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "PDE5 inhibitor + alpha-blocker — additive hypotension",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "modeled signal",
      "evidenceStatus": "modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt",
      "evidenceRefs": [],
      "evidenceSources": [],
      "sourceUrls": [],
      "sourceLinked": false,
      "provenanceStatus": "modeled signal",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": false,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=sildenafil,tamsulosin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-sildenafil-tamsulosin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "sildenafil-tamsulosin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-ibuprofen-lisinopril",
      "label": "Ibuprofen + lisinopril",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ibuprofen",
          "name": "Ibuprofen",
          "id": "ibuprofen",
          "class": "NSAID"
        },
        {
          "input": "lisinopril",
          "name": "Lisinopril",
          "id": "lisinopril",
          "class": "ACE Inhibitor"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "High potassium risk may increase",
      "reviewQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "patientSummary": "High potassium risk may increase",
      "patientQuestion": "Can you check whether this list could raise potassium or kidney-related monitoring concerns?",
      "clinicianSummary": "High potassium risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Multiple nephrotoxic agents: Ibuprofen, Lisinopril",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "modeled signal",
      "evidenceStatus": "modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt",
      "evidenceRefs": [],
      "evidenceSources": [],
      "sourceUrls": [],
      "sourceLinked": false,
      "provenanceStatus": "modeled signal",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": false,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ibuprofen,lisinopril&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-ibuprofen-lisinopril",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ibuprofen-lisinopril",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "blood-pressure-heart-failure-terbinafine-metoprolol",
      "label": "Terbinafine + metoprolol",
      "guideId": "blood-pressure-heart-failure",
      "guideTitle": "Blood Pressure and Heart Failure",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "terbinafine",
          "name": "Terbinafine",
          "id": "terbinafine",
          "class": "Allylamine Antifungal"
        },
        {
          "input": "metoprolol",
          "name": "Metoprolol",
          "id": "metoprolol",
          "class": "Beta-blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Metoprolol exposure may rise with Terbinafine",
      "reviewQuestion": "Can you check whether my gene result could raise Metoprolol side effects, pulse, blood pressure, or monitoring needs?",
      "patientSummary": "Metoprolol side-effect risk may increase",
      "patientQuestion": "Can you check whether my gene result could raise Metoprolol side effects, pulse, blood pressure, or monitoring needs?",
      "clinicianSummary": "Metoprolol exposure may rise with Terbinafine",
      "mechanismSummary": "Terbinafine may increase Metoprolol exposure, raising Metoprolol toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP2D6 genetic phenotype is normal metabolizer; functional phenotype is poor function (20% capacity). Drivers: Terbinafine inhibitor. Affects Metoprolol.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 4 sources",
      "evidenceStatus": "guideline · 4 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_metoprolol_cyp2d6_cpic"
      ],
      "evidenceSources": [
        {
          "ref": "ev_metoprolol_cyp2d6_cpic",
          "title": "CPIC guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and beta-blocker therapy",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 4 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=terbinafine,metoprolol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#blood-pressure-heart-failure-terbinafine-metoprolol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "terbinafine-metoprolol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-warfarin-fluconazole-ibuprofen",
      "label": "Warfarin + fluconazole + ibuprofen",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        },
        {
          "input": "fluconazole",
          "name": "Fluconazole",
          "id": "fluconazole",
          "class": "Azole Antifungal"
        },
        {
          "input": "ibuprofen",
          "name": "Ibuprofen",
          "id": "ibuprofen",
          "class": "NSAID"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Bleeding burden may rise",
      "reviewQuestion": "Can you check whether Warfarin + Ibuprofen needs closer bleeding or clotting monitoring?",
      "patientSummary": "Warfarin bleeding risk may increase",
      "patientQuestion": "Can you check whether Warfarin + Ibuprofen needs closer bleeding or clotting monitoring?",
      "clinicianSummary": "Bleeding burden may rise",
      "mechanismSummary": "Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "CYP2C9 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Fluconazole inhibitor, current stack substrate burden. Affects Warfarin, Ibuprofen.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 6 sources",
      "evidenceStatus": "guideline · 6 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_cyp2c9_nsaid_cpic2020",
        "ev_warfarin_nsaid_bleed",
        "ev_fluconazole_warfarin_black1996"
      ],
      "evidenceSources": [
        {
          "ref": "ev_cyp2c9_nsaid_cpic2020",
          "title": "CPIC Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs",
          "type": "guideline",
          "pmid": "32189324",
          "doi": "10.1002/cpt.1830",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32189324/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_warfarin_nsaid_bleed",
          "title": "Risk of upper gastrointestinal bleeding with warfarin and NSAIDs: a case-control study",
          "type": "observational",
          "pmid": "11176762",
          "doi": "10.1001/archinte.161.2.189",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11176762/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_fluconazole_warfarin_black1996",
          "title": "Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies",
          "type": "clinical_pk",
          "pmid": "8801057",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8801057/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/32189324/",
        "https://pubmed.ncbi.nlm.nih.gov/11176762/",
        "https://pubmed.ncbi.nlm.nih.gov/8801057/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 6 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=warfarin,fluconazole,ibuprofen&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-warfarin-fluconazole-ibuprofen",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "warfarin-fluconazole-ibuprofen",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-warfarin-tmp-smx",
      "label": "Warfarin + TMP-SMX",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        },
        {
          "input": "trimethoprim_sulfamethoxazole",
          "name": "Trimethoprim/Sulfamethoxazole",
          "id": "trimethoprim_sulfamethoxazole",
          "class": "Sulfonamide Antibiotic / Folate Antagonist"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Bleeding burden may rise",
      "reviewQuestion": "Can you check whether Warfarin + Trimethoprim/Sulfamethoxazole needs closer bleeding or clotting monitoring?",
      "patientSummary": "Warfarin bleeding risk may increase",
      "patientQuestion": "Can you check whether Warfarin + Trimethoprim/Sulfamethoxazole needs closer bleeding or clotting monitoring?",
      "clinicianSummary": "Bleeding burden may rise",
      "mechanismSummary": "Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "CYP2C9 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (45% capacity). Drivers: Trimethoprim/Sulfamethoxazole inhibitor, current stack substrate burden. Affects Warfarin, Trimeth...",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tmp_smx_label",
        "ev_warfarin_abx_lane2014"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tmp_smx_label",
          "title": "Sulfamethoxazole/trimethoprim prescribing information - warfarin, OCT2/CYP2C8, and folate-toxicity context",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_warfarin_abx_lane2014",
          "title": "Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans",
          "type": "observational",
          "pmid": "24657899",
          "doi": "10.1016/j.amjmed.2014.01.044",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24657899/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://pubmed.ncbi.nlm.nih.gov/24657899/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=warfarin,trimethoprim_sulfamethoxazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-warfarin-tmp-smx",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "warfarin-tmp-smx",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-clopidogrel-omeprazole-cyp2c19-pm",
      "label": "Clopidogrel + omeprazole with CYP2C19 PM",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "clopidogrel",
          "name": "Clopidogrel",
          "id": "clopidogrel",
          "class": "Antiplatelet"
        },
        {
          "input": "omeprazole",
          "name": "Omeprazole",
          "id": "omeprazole",
          "class": "PPI"
        }
      ],
      "genotypes": [
        "CYP2C19:PM"
      ],
      "severity": "critical",
      "priority": "critical",
      "summary": "Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole",
      "reviewQuestion": "Can you check whether Clopidogrel may work less well with my current list?",
      "patientSummary": "Clopidogrel may work less well with Omeprazole",
      "patientQuestion": "Can you check whether Clopidogrel may work less well with my current list?",
      "clinicianSummary": "Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole",
      "mechanismSummary": "Increased stent thrombosis and MI risk. FDA warning Additional grouped signal: Clopidogrel exposure may fall with Omeprazole; CYP2C19 behaves as poor function. Related genotype, pathway, and metabolite signals are grouped below.",
      "clinicalRationale": "CYP2C19 genetic phenotype is poor metabolizer; functional phenotype is poor function (15% capacity). Drivers: CYP2C19 genotype, Omeprazole inhibitor, current stack substrate burden. Affects Clopidogrel, Omeprazole.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · rct · 7 sources",
      "evidenceStatus": "rct · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_clopidogrel_cyp2c19_cpic",
        "ev_omeprazole_cyp2c19_lima2021",
        "ev_clopidogrel_active_thiol_kim2014",
        "ev_clopidogrel_cyp2c19_mega2009",
        "ev_clopidogrel_dose_escalation_horenstein2014"
      ],
      "evidenceSources": [
        {
          "ref": "ev_clopidogrel_cyp2c19_cpic",
          "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update",
          "type": "guideline",
          "pmid": "35034351",
          "doi": "10.1002/cpt.2526",
          "url": "https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351.pdf",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_omeprazole_cyp2c19_lima2021",
          "title": "CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing",
          "type": "guideline",
          "pmid": "32770672",
          "doi": "10.1002/cpt.1168",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32770672/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        },
        {
          "ref": "ev_clopidogrel_active_thiol_kim2014",
          "title": "CYP2C19 phenotype effect on clopidogrel active thiol metabolite exposure and platelet inhibition",
          "type": "clinical_pk",
          "pmid": "25196410",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25196410/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_clopidogrel_cyp2c19_mega2009",
          "title": "Cytochrome P-450 polymorphisms and response to clopidogrel",
          "type": "rct",
          "pmid": "19106084",
          "doi": "10.1056/NEJMoa0809171",
          "url": "https://pubmed.ncbi.nlm.nih.gov/19106084/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_clopidogrel_dose_escalation_horenstein2014",
          "title": "Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers",
          "type": "clinical_pk",
          "pmid": "24710841",
          "doi": "10.1002/jcph.293",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24710841/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351.pdf",
        "https://pubmed.ncbi.nlm.nih.gov/32770672/",
        "https://pubmed.ncbi.nlm.nih.gov/25196410/",
        "https://pubmed.ncbi.nlm.nih.gov/19106084/",
        "https://pubmed.ncbi.nlm.nih.gov/24710841/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · rct · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=clopidogrel,omeprazole&genotype=CYP2C19:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-clopidogrel-omeprazole-cyp2c19-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "clopidogrel-omeprazole-cyp2c19-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-apixaban-clarithromycin",
      "label": "Apixaban + clarithromycin",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "apixaban",
          "name": "Apixaban",
          "id": "apixaban",
          "class": "DOAC"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Apixaban exposure may rise with Clarithromycin",
      "reviewQuestion": "Can you check whether Apixaban side effects or monitoring needs could increase?",
      "patientSummary": "Apixaban side-effect risk may increase",
      "patientQuestion": "Can you check whether Apixaban side effects or monitoring needs could increase?",
      "clinicianSummary": "Apixaban exposure may rise with Clarithromycin",
      "mechanismSummary": "Clarithromycin may increase Apixaban exposure, raising Apixaban toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Apixaban, Clarithromycin.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 7 sources",
      "evidenceStatus": "fda label · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_abcb1_pgp_variant_summary",
        "ev_doac_rifampin_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_abcb1_pgp_variant_summary",
          "title": "ABCB1/P-glycoprotein pharmacogenetic variants and P-gp substrate exposure",
          "type": "observational",
          "pmid": "20170205",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/20170205/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_doac_rifampin_label",
          "title": "Direct oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/20170205/",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=apixaban,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-apixaban-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "apixaban-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-apixaban-rifampin",
      "label": "Apixaban + rifampin",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "apixaban",
          "name": "Apixaban",
          "id": "apixaban",
          "class": "DOAC"
        },
        {
          "input": "rifampin",
          "name": "Rifampin",
          "id": "rifampin",
          "class": "Rifamycin"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Apixaban exposure may rise with Rifampin",
      "reviewQuestion": "Can you check whether Apixaban side effects or monitoring needs could increase?",
      "patientSummary": "Apixaban may work less well",
      "patientQuestion": "Can you check whether Apixaban side effects or monitoring needs could increase?",
      "clinicianSummary": "Apixaban exposure may rise with Rifampin",
      "mechanismSummary": "Rifampin may increase Apixaban exposure, raising Apixaban toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Rifampin induces CYP3A4 and P-gp, reducing apixaban AUC by ~54%",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_doac_rifampin_hartter2012",
        "ev_doac_rifampin_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_doac_rifampin_hartter2012",
          "title": "Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin",
          "type": "clinical_pk",
          "pmid": "22348256",
          "doi": "10.1111/j.1365-2125.2012.04218.x",
          "url": "https://pubmed.ncbi.nlm.nih.gov/22348256/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_doac_rifampin_label",
          "title": "Direct oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/22348256/",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=apixaban,rifampin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-apixaban-rifampin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "apixaban-rifampin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-amiodarone-warfarin",
      "label": "Amiodarone + warfarin",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "amiodarone",
          "name": "Amiodarone",
          "id": "amiodarone",
          "class": "Antiarrhythmic"
        },
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Warfarin INR sensitivity may increase",
      "reviewQuestion": "Can you check whether Warfarin side effects or monitoring needs could increase?",
      "patientSummary": "Warfarin side-effect risk may increase",
      "patientQuestion": "Can you check whether Warfarin side effects or monitoring needs could increase?",
      "clinicianSummary": "Warfarin INR sensitivity may increase",
      "mechanismSummary": "Amiodarone may increase Warfarin exposure, raising Warfarin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (50% capacity). Drivers: Amiodarone inhibitor. Affects Amiodarone, Warfarin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 7 sources",
      "evidenceStatus": "guideline · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_amiodarone_warfarin_kerin1988",
        "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017"
      ],
      "evidenceSources": [
        {
          "ref": "ev_amiodarone_warfarin_kerin1988",
          "title": "The incidence, magnitude, and time course of the amiodarone-warfarin interaction",
          "type": "clinical_pk",
          "pmid": "3401099",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3401099/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017",
          "title": "CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update",
          "type": "guideline",
          "pmid": "28198005",
          "doi": "10.1002/cpt.668",
          "url": "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/3401099/",
        "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=amiodarone,warfarin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-amiodarone-warfarin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "amiodarone-warfarin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-warfarin-acetaminophen",
      "label": "Warfarin + acetaminophen",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        },
        {
          "input": "acetaminophen",
          "name": "Acetaminophen",
          "id": "acetaminophen",
          "class": "Analgesic"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Acetaminophen exposure may rise with Warfarin",
      "reviewQuestion": "Can you check whether Acetaminophen side effects or monitoring needs could increase?",
      "patientSummary": "Acetaminophen side-effect risk may increase",
      "patientQuestion": "Can you check whether Acetaminophen side effects or monitoring needs could increase?",
      "clinicianSummary": "Acetaminophen exposure may rise with Warfarin",
      "mechanismSummary": "Warfarin may increase Acetaminophen exposure, raising Acetaminophen toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Acetaminophen's metabolite NAPQI inhibits vitamin K-dependent clotting factor synthesis at doses >2g/day",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "modeled signal",
      "evidenceStatus": "modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt",
      "evidenceRefs": [],
      "evidenceSources": [],
      "sourceUrls": [],
      "sourceLinked": false,
      "provenanceStatus": "modeled signal",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": false,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=warfarin,acetaminophen&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-warfarin-acetaminophen",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "warfarin-acetaminophen",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "anticoagulants-antiplatelets-dabigatran-rifampin",
      "label": "Dabigatran + rifampin",
      "guideId": "anticoagulants-antiplatelets",
      "guideTitle": "Anticoagulants and Antiplatelets",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "dabigatran",
          "name": "Dabigatran",
          "id": "dabigatran",
          "class": "DOAC"
        },
        {
          "input": "rifampin",
          "name": "Rifampin",
          "id": "rifampin",
          "class": "Rifamycin"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Rifampin absorption may fall with Dabigatran",
      "reviewQuestion": "Can you check whether Rifampin may not absorb as expected with my current list?",
      "patientSummary": "Rifampin may not absorb as expected",
      "patientQuestion": "Can you check whether Rifampin may not absorb as expected with my current list?",
      "clinicianSummary": "Rifampin absorption may fall with Dabigatran",
      "mechanismSummary": "Loss of anticoagulation — avoid/contraindicated Additional grouped signal: Dabigatran transport may change with Rifampin.",
      "clinicalRationale": "Rifampin induces P-gp, reducing dabigatran etexilate absorption and dabigatran AUC by ~67%",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_doac_rifampin_hartter2012",
        "ev_doac_rifampin_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_doac_rifampin_hartter2012",
          "title": "Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin",
          "type": "clinical_pk",
          "pmid": "22348256",
          "doi": "10.1111/j.1365-2125.2012.04218.x",
          "url": "https://pubmed.ncbi.nlm.nih.gov/22348256/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_doac_rifampin_label",
          "title": "Direct oral anticoagulant Prescribing Information — combined P-gp and strong CYP3A4 inducers",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/22348256/",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=dabigatran,rifampin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#anticoagulants-antiplatelets-dabigatran-rifampin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "dabigatran-rifampin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-metformin-tmp-smx",
      "label": "Metformin + TMP-SMX",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "metformin",
          "name": "Metformin",
          "id": "metformin",
          "class": "Biguanide"
        },
        {
          "input": "trimethoprim_sulfamethoxazole",
          "name": "Trimethoprim/Sulfamethoxazole",
          "id": "trimethoprim_sulfamethoxazole",
          "class": "Sulfonamide Antibiotic / Folate Antagonist"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Metformin exposure may rise with Trimethoprim/Sulfamethoxazole",
      "reviewQuestion": "Can you check whether Metformin side effects or monitoring needs could increase?",
      "patientSummary": "Metformin side-effect risk may increase",
      "patientQuestion": "Can you check whether Metformin side effects or monitoring needs could increase?",
      "clinicianSummary": "Metformin exposure may rise with Trimethoprim/Sulfamethoxazole",
      "mechanismSummary": "Trimethoprim/Sulfamethoxazole may increase Metformin exposure, raising Metformin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Trimethoprim inhibits OCT2 and MATE1, reducing metformin renal secretion by ~40%",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "modeled signal",
      "evidenceStatus": "modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt",
      "evidenceRefs": [],
      "evidenceSources": [],
      "sourceUrls": [],
      "sourceLinked": false,
      "provenanceStatus": "modeled signal",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": false,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=metformin,trimethoprim_sulfamethoxazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-metformin-tmp-smx",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "metformin-tmp-smx",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-dolutegravir-metformin",
      "label": "Dolutegravir + metformin",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "dolutegravir",
          "name": "Dolutegravir",
          "id": "dolutegravir",
          "class": "Integrase Inhibitor"
        },
        {
          "input": "metformin",
          "name": "Metformin",
          "id": "metformin",
          "class": "Biguanide"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Metformin exposure may rise with Dolutegravir",
      "reviewQuestion": "Can you check whether Metformin side effects or monitoring needs could increase?",
      "patientSummary": "Metformin side-effect risk may increase",
      "patientQuestion": "Can you check whether Metformin side effects or monitoring needs could increase?",
      "clinicianSummary": "Metformin exposure may rise with Dolutegravir",
      "mechanismSummary": "Dolutegravir may increase Metformin exposure, raising Metformin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Dolutegravir inhibits renal OCT2 and MATE1 transporters, blocking the clearance vectors for metformin.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_dolutegravir_oct2_mate1_fda"
      ],
      "evidenceSources": [
        {
          "ref": "ev_dolutegravir_oct2_mate1_fda",
          "title": "Tivicay (dolutegravir) Full Prescribing Information — Transporter Inhibition Profiles",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://www.accessdata.fda.gov/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://www.accessdata.fda.gov/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=dolutegravir,metformin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-dolutegravir-metformin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "dolutegravir-metformin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-ranolazine-metformin",
      "label": "Ranolazine + metformin",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ranolazine",
          "name": "Ranolazine",
          "id": "ranolazine",
          "class": "Antianginal / Late Sodium Current Inhibitor"
        },
        {
          "input": "metformin",
          "name": "Metformin",
          "id": "metformin",
          "class": "Biguanide"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Ranolazine exposure may rise with Metformin",
      "reviewQuestion": "Can you check whether Ranolazine side effects or monitoring needs could increase?",
      "patientSummary": "Ranolazine side-effect risk may increase",
      "patientQuestion": "Can you check whether Ranolazine side effects or monitoring needs could increase?",
      "clinicianSummary": "Ranolazine exposure may rise with Metformin",
      "mechanismSummary": "Metformin may increase Ranolazine exposure, raising Ranolazine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Ranolazine inhibits OCT2-mediated metformin renal handling.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_ranolazine_cyp3a_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_ranolazine_cyp3a_label",
          "title": "Ranolazine prescribing information - CYP3A inhibitors, QT prolongation, and OCT2 substrates",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ranolazine,metformin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-ranolazine-metformin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ranolazine-metformin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-insulin-glargine-metoprolol",
      "label": "Insulin glargine + metoprolol",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "insulin_glargine",
          "name": "Insulin Glargine",
          "id": "insulin_glargine",
          "class": "Long-Acting Insulin / Basal Insulin"
        },
        {
          "input": "metoprolol",
          "name": "Metoprolol",
          "id": "metoprolol",
          "class": "Beta-blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Pharmacodynamic risk may increase",
      "reviewQuestion": "Can you check whether Metoprolol + Insulin Glargine needs closer review?",
      "patientSummary": "Safety note for Metoprolol + Insulin Glargine",
      "patientQuestion": "Can you check whether Metoprolol + Insulin Glargine needs closer review?",
      "clinicianSummary": "Pharmacodynamic risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Beta-blockers can blunt adrenergic warning symptoms of hypoglycemia in patients using insulin.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_insulin_glargine_beta_blocker_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_insulin_glargine_beta_blocker_label",
          "title": "Insulin glargine prescribing information - hypoglycemia masking and insulin combination risk",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=insulin_glargine,metoprolol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-insulin-glargine-metoprolol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "insulin-glargine-metoprolol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-insulin-lispro-metoprolol",
      "label": "Insulin lispro + metoprolol",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "insulin_lispro",
          "name": "Insulin Lispro",
          "id": "insulin_lispro",
          "class": "Rapid-Acting Insulin"
        },
        {
          "input": "metoprolol",
          "name": "Metoprolol",
          "id": "metoprolol",
          "class": "Beta-blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Pharmacodynamic risk may increase",
      "reviewQuestion": "Can you check whether Metoprolol + Insulin Lispro needs closer review?",
      "patientSummary": "Safety note for Metoprolol + Insulin Lispro",
      "patientQuestion": "Can you check whether Metoprolol + Insulin Lispro needs closer review?",
      "clinicianSummary": "Pharmacodynamic risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Beta-blockers can blunt adrenergic warning symptoms of hypoglycemia in patients using rapid-acting insulin.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_insulin_glargine_beta_blocker_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_insulin_glargine_beta_blocker_label",
          "title": "Insulin glargine prescribing information - hypoglycemia masking and insulin combination risk",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=insulin_lispro,metoprolol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-insulin-lispro-metoprolol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "insulin-lispro-metoprolol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-insulin-glargine-tirzepatide",
      "label": "Insulin glargine + tirzepatide",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "insulin_glargine",
          "name": "Insulin Glargine",
          "id": "insulin_glargine",
          "class": "Long-Acting Insulin / Basal Insulin"
        },
        {
          "input": "tirzepatide",
          "name": "Tirzepatide",
          "id": "tirzepatide",
          "class": "GIP/GLP-1 Receptor Agonist"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Pharmacodynamic risk may increase",
      "reviewQuestion": "Can you check whether Tirzepatide + Insulin Glargine needs closer review?",
      "patientSummary": "Safety note for Tirzepatide + Insulin Glargine",
      "patientQuestion": "Can you check whether Tirzepatide + Insulin Glargine needs closer review?",
      "clinicianSummary": "Pharmacodynamic risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Tirzepatide improves glycemic control and can increase hypoglycemia risk when combined with insulin.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_insulin_glargine_beta_blocker_label",
        "ev_tirzepatide_oral_absorption_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_insulin_glargine_beta_blocker_label",
          "title": "Insulin glargine prescribing information - hypoglycemia masking and insulin combination risk",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_tirzepatide_oral_absorption_label",
          "title": "Tirzepatide prescribing information - delayed gastric emptying and oral medications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=insulin_glargine,tirzepatide&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-insulin-glargine-tirzepatide",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "insulin-glargine-tirzepatide",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "diabetes-weight-loss-tirzepatide-warfarin",
      "label": "Tirzepatide + warfarin",
      "guideId": "diabetes-weight-loss",
      "guideTitle": "Diabetes and Weight-Loss Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "tirzepatide",
          "name": "Tirzepatide",
          "id": "tirzepatide",
          "class": "GIP/GLP-1 Receptor Agonist"
        },
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        }
      ],
      "genotypes": [],
      "severity": "monitor",
      "priority": "monitor",
      "summary": "Tirzepatide absorption may change with Warfarin",
      "reviewQuestion": "Can you check whether Tirzepatide may not absorb as expected with my current list?",
      "patientSummary": "Tirzepatide may not absorb as expected",
      "patientQuestion": "Can you check whether Tirzepatide may not absorb as expected with my current list?",
      "clinicianSummary": "Tirzepatide absorption may change with Warfarin",
      "mechanismSummary": "Monitor INR after tirzepatide initiation or dose escalation if warfarin control changes.",
      "clinicalRationale": "Tirzepatide delays gastric emptying and can alter oral drug absorption timing; warfarin has a narrow therapeutic margin.",
      "reviewFocus": "Review this supporting context with symptoms, doses, timing, and the rest of the medication list.",
      "reviewAction": "Review this supporting context with symptoms, doses, timing, and the rest of the medication list.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tirzepatide_oral_absorption_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tirzepatide_oral_absorption_label",
          "title": "Tirzepatide prescribing information - delayed gastric emptying and oral medications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=tirzepatide,warfarin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#diabetes-weight-loss-tirzepatide-warfarin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "tirzepatide-warfarin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-warfarin-ibuprofen",
      "label": "Warfarin + ibuprofen",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        },
        {
          "input": "ibuprofen",
          "name": "Ibuprofen",
          "id": "ibuprofen",
          "class": "NSAID"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Bleeding burden may rise",
      "reviewQuestion": "Can you check whether Warfarin + Ibuprofen needs closer bleeding or clotting monitoring?",
      "patientSummary": "Warfarin bleeding risk may increase",
      "patientQuestion": "Can you check whether Warfarin + Ibuprofen needs closer bleeding or clotting monitoring?",
      "clinicianSummary": "Bleeding burden may rise",
      "mechanismSummary": "Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Multiple agents affecting hemostasis: Warfarin (Anticoagulant), Ibuprofen (NSAID)",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "primary-literature linked · observational · 1 source",
      "evidenceStatus": "observational · 1 source · mechanistic moderate · primary-literature linked",
      "evidenceRefs": [
        "ev_warfarin_nsaid_bleed"
      ],
      "evidenceSources": [
        {
          "ref": "ev_warfarin_nsaid_bleed",
          "title": "Risk of upper gastrointestinal bleeding with warfarin and NSAIDs: a case-control study",
          "type": "observational",
          "pmid": "11176762",
          "doi": "10.1001/archinte.161.2.189",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11176762/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/11176762/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · observational · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=warfarin,ibuprofen&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-warfarin-ibuprofen",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "warfarin-ibuprofen",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-lithium-naproxen",
      "label": "Lithium + naproxen",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "lithium",
          "name": "Lithium",
          "id": "lithium",
          "class": "Mood Stabilizer"
        },
        {
          "input": "naproxen",
          "name": "Naproxen",
          "id": "naproxen",
          "class": "NSAID"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Lithium exposure may rise with Naproxen",
      "reviewQuestion": "Can you check whether Lithium side effects or monitoring needs could increase?",
      "patientSummary": "Lithium side-effect risk may increase",
      "patientQuestion": "Can you check whether Lithium side effects or monitoring needs could increase?",
      "clinicianSummary": "Lithium exposure may rise with Naproxen",
      "mechanismSummary": "Naproxen may increase Lithium exposure, raising Lithium toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "NSAIDs reduce lithium renal clearance",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "primary-literature linked · clinical pk · 1 source",
      "evidenceStatus": "clinical pk · 1 source · mechanistic high · primary-literature linked",
      "evidenceRefs": [
        "ev_lithium_nsaid_clearance"
      ],
      "evidenceSources": [
        {
          "ref": "ev_lithium_nsaid_clearance",
          "title": "Nonsteroidal anti-inflammatory drugs and lithium: a case report and review of the literature",
          "type": "clinical_pk",
          "pmid": "2258452",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/2258452/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/2258452/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · clinical pk · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=lithium,naproxen&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-lithium-naproxen",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "lithium-naproxen",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-methotrexate-ibuprofen",
      "label": "Methotrexate + ibuprofen",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "methotrexate",
          "name": "Methotrexate",
          "id": "methotrexate",
          "class": "DMARD"
        },
        {
          "input": "ibuprofen",
          "name": "Ibuprofen",
          "id": "ibuprofen",
          "class": "NSAID"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Methotrexate exposure may rise with Ibuprofen",
      "reviewQuestion": "Can you check whether this combination could make Methotrexate side effects or lab problems stronger?",
      "patientSummary": "Methotrexate side effects may increase",
      "patientQuestion": "Can you check whether this combination could make Methotrexate side effects or lab problems stronger?",
      "clinicianSummary": "Methotrexate exposure may rise with Ibuprofen",
      "mechanismSummary": "Ibuprofen may increase Methotrexate exposure, raising Methotrexate toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "NSAIDs reduce methotrexate renal clearance",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "primary-literature linked · clinical pk · 1 source",
      "evidenceStatus": "clinical pk · 1 source · mechanistic high · primary-literature linked",
      "evidenceRefs": [
        "ev_mtx_interactions_bannwarth1996"
      ],
      "evidenceSources": [
        {
          "ref": "ev_mtx_interactions_bannwarth1996",
          "title": "Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis",
          "type": "clinical_pk",
          "pmid": "8882301",
          "doi": "10.2165/00003088-199630030-00002",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8882301/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/8882301/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · clinical pk · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=methotrexate,ibuprofen&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-methotrexate-ibuprofen",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "methotrexate-ibuprofen",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-fluoxetine-tramadol-cyp2d6-pm",
      "label": "Fluoxetine + tramadol with CYP2D6 PM",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "fluoxetine",
          "name": "Fluoxetine",
          "id": "fluoxetine",
          "class": "SSRI"
        },
        {
          "input": "tramadol",
          "name": "Tramadol",
          "id": "tramadol",
          "class": "Opioid"
        }
      ],
      "genotypes": [
        "CYP2D6:PM"
      ],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Switching and washout timing may need review",
      "reviewQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "patientSummary": "Timing may need review",
      "patientQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "clinicianSummary": "Switching and washout timing may need review",
      "mechanismSummary": "Timing and persistence context may remain relevant after stopping or switching. Parent, metabolite, and recovery signals are grouped below.",
      "clinicalRationale": "Fluoxetine/norfluoxetine CYP2D6: ~5 weeks for enzyme resynthesis; Modeled timing context: 35 days before assuming baseline recovery.",
      "reviewFocus": "Review stop date, switch timing, enzyme recovery, and active-metabolite persistence before applying standard timing assumptions.",
      "reviewAction": "Review stop date, switch timing, enzyme recovery, and active-metabolite persistence before applying standard timing assumptions.",
      "evidenceSummary": "authority-linked · fda label · 7 sources",
      "evidenceStatus": "fda label · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_fluoxetine_cyp2d6_fda",
        "ev_fluoxetine_cyp2d6_sunkara2010",
        "ev_fluoxetine_desipramine_preskorn1994",
        "ev_ssri_cyp2d6_review"
      ],
      "evidenceSources": [
        {
          "ref": "ev_fluoxetine_cyp2d6_fda",
          "title": "Prozac (fluoxetine) Prescribing Information — Drug Interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7a4db7f-cdac-2b36-e053-2995a90a8d64",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_fluoxetine_cyp2d6_sunkara2010",
          "title": "Stereoselective pharmacokinetics of fluoxetine and norfluoxetine in CYP2D6 poor and extensive metabolizers",
          "type": "clinical_pk",
          "pmid": "20184222",
          "doi": "10.1002/jcph.39",
          "url": "https://pubmed.ncbi.nlm.nih.gov/20184222/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_fluoxetine_desipramine_preskorn1994",
          "title": "Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine",
          "type": "clinical_pk",
          "pmid": "37754235",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37754235/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_ssri_cyp2d6_review",
          "title": "Pharmacokinetic-pharmacodynamic relationships of SSRIs — CYP inhibition rank order",
          "type": "meta_analysis",
          "pmid": "8968657",
          "doi": "10.2165/00003088-199631060-00004",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8968657/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7a4db7f-cdac-2b36-e053-2995a90a8d64",
        "https://pubmed.ncbi.nlm.nih.gov/20184222/",
        "https://pubmed.ncbi.nlm.nih.gov/37754235/",
        "https://pubmed.ncbi.nlm.nih.gov/8968657/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=fluoxetine,tramadol&genotype=CYP2D6:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-fluoxetine-tramadol-cyp2d6-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "fluoxetine-tramadol-cyp2d6-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-bupropion-codeine-cyp2d6-pm",
      "label": "Bupropion + codeine with CYP2D6 PM",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "bupropion",
          "name": "Bupropion",
          "id": "bupropion",
          "class": "Atypical AD"
        },
        {
          "input": "codeine",
          "name": "Codeine",
          "id": "codeine",
          "class": "Opioid"
        }
      ],
      "genotypes": [
        "CYP2D6:PM"
      ],
      "severity": "severe",
      "priority": "severe",
      "summary": "Codeine activation to Morphine may be reduced with Bupropion",
      "reviewQuestion": "Can you check whether Codeine may work less well with my current list?",
      "patientSummary": "Codeine side-effect risk may increase",
      "patientQuestion": "Can you check whether Codeine may work less well with my current list?",
      "clinicianSummary": "Codeine activation to Morphine may be reduced with Bupropion",
      "mechanismSummary": "Bupropion may increase Codeine exposure, raising Codeine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP2D6 genetic phenotype is poor metabolizer; functional phenotype is minimal/no function (4% capacity). Drivers: CYP2D6 genotype, Bupropion inhibitor. Affects Codeine.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_bupropion_cyp2d6_fda",
        "ev_bupropion_cyp2d6_hesse1996",
        "ev_opioid_cyp2d6_cpic_2020",
        "ev_codeine_cyp2d6_cpic",
        "ev_codeine_ultrarapid_deaths"
      ],
      "evidenceSources": [
        {
          "ref": "ev_bupropion_cyp2d6_fda",
          "title": "Wellbutrin (bupropion) Prescribing Information — Drug Interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bupropion",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_bupropion_cyp2d6_hesse1996",
          "title": "Bupropion plasma levels and CYP2D6 phenotype",
          "type": "observational",
          "pmid": "8885123",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8885123/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_opioid_cyp2d6_cpic_2020",
          "title": "CPIC guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy",
          "type": "guideline",
          "pmid": "33387367",
          "doi": "",
          "url": "https://cpicpgx.org/content/guideline/publication/opioids/2020/CPIC_opioids_PREPRINT.pdf",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_codeine_cyp2d6_cpic",
          "title": "CPIC Guideline for Codeine and CYP2D6",
          "type": "guideline",
          "pmid": "24458010",
          "doi": "10.1038/clpt.2013.254",
          "url": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_codeine_ultrarapid_deaths",
          "title": "Fatal respiratory depression in neonates — mother CYP2D6 ultrarapid metabolizer on codeine",
          "type": "case_report",
          "pmid": "16950362",
          "doi": "10.1016/S0140-6736(06)69255-6",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16950362/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bupropion",
        "https://pubmed.ncbi.nlm.nih.gov/8885123/",
        "https://cpicpgx.org/content/guideline/publication/opioids/2020/CPIC_opioids_PREPRINT.pdf",
        "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
        "https://pubmed.ncbi.nlm.nih.gov/16950362/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=bupropion,codeine&genotype=CYP2D6:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-bupropion-codeine-cyp2d6-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "bupropion-codeine-cyp2d6-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-sertraline-sumatriptan",
      "label": "Sertraline + sumatriptan",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "sertraline",
          "name": "Sertraline",
          "id": "sertraline",
          "class": "SSRI"
        },
        {
          "input": "sumatriptan",
          "name": "Sumatriptan",
          "id": "sumatriptan",
          "class": "Triptan"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Serotonin toxicity may rise",
      "reviewQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "patientSummary": "Serotonin-related side effects may increase",
      "patientQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "clinicianSummary": "Serotonin toxicity may rise",
      "mechanismSummary": "Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Multiple serotonergic agents: Sertraline, Sumatriptan",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "modeled signal",
      "evidenceStatus": "modeled review prompt · no linked sources · mechanistic moderate · modeled review prompt",
      "evidenceRefs": [],
      "evidenceSources": [],
      "sourceUrls": [],
      "sourceLinked": false,
      "provenanceStatus": "modeled signal",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": false,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=sertraline,sumatriptan&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-sertraline-sumatriptan",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "sertraline-sumatriptan",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-duloxetine-tizanidine",
      "label": "Duloxetine + tizanidine",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "duloxetine",
          "name": "Duloxetine",
          "id": "duloxetine",
          "class": "SNRI"
        },
        {
          "input": "tizanidine",
          "name": "Tizanidine",
          "id": "tizanidine",
          "class": "Muscle Relaxant"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Tizanidine exposure may rise with Duloxetine",
      "reviewQuestion": "Can you check whether Tizanidine side effects or monitoring needs could increase?",
      "patientSummary": "Tizanidine side-effect risk may increase",
      "patientQuestion": "Can you check whether Tizanidine side effects or monitoring needs could increase?",
      "clinicianSummary": "Tizanidine exposure may rise with Duloxetine",
      "mechanismSummary": "Duloxetine may increase Tizanidine exposure, raising Tizanidine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Moderate-to-strong competitive inhibition of hepatic CYP1A2 networks.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tizanidine_cyp1a2_contraindication"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tizanidine_cyp1a2_contraindication",
          "title": "Zanaflex (tizanidine) Oral Prescribing Information — Core Drug Interaction Safety Profiles",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://www.accessdata.fda.gov/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://www.accessdata.fda.gov/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=duloxetine,tizanidine&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-duloxetine-tizanidine",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "duloxetine-tizanidine",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "pain-inflammation-migraine-phenelzine-tramadol",
      "label": "Phenelzine + tramadol",
      "guideId": "pain-inflammation-migraine",
      "guideTitle": "Pain, Inflammation, and Migraine",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "phenelzine",
          "name": "Phenelzine",
          "id": "phenelzine",
          "class": "MAOI"
        },
        {
          "input": "tramadol",
          "name": "Tramadol",
          "id": "tramadol",
          "class": "Opioid"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Serotonin toxicity may rise",
      "reviewQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "patientSummary": "Serotonin-related side effects may increase",
      "patientQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "clinicianSummary": "Serotonin toxicity may rise",
      "mechanismSummary": "Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "MAO-A inhibition + tramadol's serotonin reuptake inhibition + weak MAOI activity of parent compound. Serotonin syndrome + seizure risk.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_maoi_ssri_serotonin_fda"
      ],
      "evidenceSources": [
        {
          "ref": "ev_maoi_ssri_serotonin_fda",
          "title": "FDA labels for MAOIs (phenelzine, tranylcypromine) — contraindication with serotonergic agents",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=phenelzine,tramadol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#pain-inflammation-migraine-phenelzine-tramadol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "phenelzine-tramadol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "psychiatry-neurology-amitriptyline-diazepam-diphenhydramine-cyp2d6-pm",
      "label": "Amitriptyline + diazepam + diphenhydramine with CYP2D6 PM",
      "guideId": "psychiatry-neurology",
      "guideTitle": "Psychiatry, Neurology, Sleep, and OTC Sedating Medicines",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "amitriptyline",
          "name": "Amitriptyline",
          "id": "amitriptyline",
          "class": "TCA"
        },
        {
          "input": "diazepam",
          "name": "Diazepam",
          "id": "diazepam",
          "class": "Benzodiazepine"
        },
        {
          "input": "diphenhydramine",
          "name": "Diphenhydramine",
          "id": "diphenhydramine",
          "class": "Antihistamine"
        }
      ],
      "genotypes": [
        "CYP2D6:PM"
      ],
      "severity": "severe",
      "priority": "severe",
      "summary": "Amitriptyline activation to 10-Hydroxyamitriptyline may be reduced with Diphenhydramine",
      "reviewQuestion": "Can you check whether Amitriptyline may work less well with my current list?",
      "patientSummary": "Amitriptyline may work less well with Diphenhydramine",
      "patientQuestion": "Can you check whether Amitriptyline may work less well with my current list?",
      "clinicianSummary": "Amitriptyline activation to 10-Hydroxyamitriptyline may be reduced with Diphenhydramine",
      "mechanismSummary": "↑ Anticholinergic burden (confusion, dry mouth, constipation, urinary retention) Additional grouped signal: CYP2D6 behaves as poor function; Amitriptyline exposure may rise with Diphenhydramine. Related genotype, pathway, and metabolite signals are grouped below.",
      "clinicalRationale": "CYP2D6 genetic phenotype is poor metabolizer; functional phenotype is poor function (10% capacity). Drivers: CYP2D6 genotype, Diphenhydramine inhibitor, current stack substrate burden. Affects Amitriptyline, Diphenhyd...",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "modeled context · modeled context · 3 sources",
      "evidenceStatus": "modeled context · 3 sources · mechanistic moderate · modeled context · not severity-bearing",
      "evidenceRefs": [],
      "evidenceSources": [],
      "sourceUrls": [],
      "sourceLinked": false,
      "provenanceStatus": "modeled context · modeled context · 3 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": false,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=amitriptyline,diazepam,diphenhydramine&genotype=CYP2D6:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#psychiatry-neurology-amitriptyline-diazepam-diphenhydramine-cyp2d6-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "amitriptyline-diazepam-diphenhydramine-cyp2d6-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "psychiatry-neurology-lamotrigine-valproic-acid",
      "label": "Lamotrigine + valproic acid",
      "guideId": "psychiatry-neurology",
      "guideTitle": "Psychiatry, Neurology, Sleep, and OTC Sedating Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "lamotrigine",
          "name": "Lamotrigine",
          "id": "lamotrigine",
          "class": "Anticonvulsant"
        },
        {
          "input": "valproic_acid",
          "name": "Valproic Acid",
          "id": "valproic_acid",
          "class": "Anticonvulsant"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Lamotrigine exposure may rise with Valproic Acid",
      "reviewQuestion": "Can you check whether Lamotrigine side effects or monitoring needs could increase?",
      "patientSummary": "Lamotrigine side-effect risk may increase",
      "patientQuestion": "Can you check whether Lamotrigine side effects or monitoring needs could increase?",
      "clinicianSummary": "Lamotrigine exposure may rise with Valproic Acid",
      "mechanismSummary": "Valproic Acid may increase Lamotrigine exposure, raising Lamotrigine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Valproate inhibits lamotrigine glucuronidation, doubling its levels",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "primary-literature linked · clinical pk · 1 source",
      "evidenceStatus": "clinical pk · 1 source · mechanistic high · primary-literature linked",
      "evidenceRefs": [
        "ev_lamotrigine_valproate_rambeck1993"
      ],
      "evidenceSources": [
        {
          "ref": "ev_lamotrigine_valproate_rambeck1993",
          "title": "Lamotrigine clinical pharmacokinetics",
          "type": "clinical_pk",
          "pmid": "8119045",
          "doi": "10.2165/00003088-199325060-00003",
          "url": "https://pubmed.ncbi.nlm.nih.gov/8119045/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/8119045/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · clinical pk · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=lamotrigine,valproic_acid&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#psychiatry-neurology-lamotrigine-valproic-acid",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "lamotrigine-valproic-acid",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "psychiatry-neurology-phenelzine-sertraline",
      "label": "Phenelzine + sertraline",
      "guideId": "psychiatry-neurology",
      "guideTitle": "Psychiatry, Neurology, Sleep, and OTC Sedating Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "phenelzine",
          "name": "Phenelzine",
          "id": "phenelzine",
          "class": "MAOI"
        },
        {
          "input": "sertraline",
          "name": "Sertraline",
          "id": "sertraline",
          "class": "SSRI"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Serotonin toxicity may rise",
      "reviewQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "patientSummary": "Serotonin-related side effects may increase",
      "patientQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "clinicianSummary": "Serotonin toxicity may rise",
      "mechanismSummary": "Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Irreversible MAO inhibition plus SERT blockade can produce excessive serotonergic signaling.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_maoi_ssri_serotonin_fda"
      ],
      "evidenceSources": [
        {
          "ref": "ev_maoi_ssri_serotonin_fda",
          "title": "FDA labels for MAOIs (phenelzine, tranylcypromine) — contraindication with serotonergic agents",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=phenelzine,sertraline&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#psychiatry-neurology-phenelzine-sertraline",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "phenelzine-sertraline",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "psychiatry-neurology-linezolid-sertraline",
      "label": "Linezolid + sertraline",
      "guideId": "psychiatry-neurology",
      "guideTitle": "Psychiatry, Neurology, Sleep, and OTC Sedating Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "linezolid",
          "name": "Linezolid",
          "id": "linezolid",
          "class": "Oxazolidinone Antibiotic"
        },
        {
          "input": "sertraline",
          "name": "Sertraline",
          "id": "sertraline",
          "class": "SSRI"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Serotonin toxicity may rise",
      "reviewQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "patientSummary": "Serotonin-related side effects may increase",
      "patientQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "clinicianSummary": "Serotonin toxicity may rise",
      "mechanismSummary": "Serotonin toxicity is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Linezolid is a reversible non-selective MAO-A/B inhibitor. Combining with any serotonergic agent risks serotonin syndrome.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_linezolid_serotonin_fda2011"
      ],
      "evidenceSources": [
        {
          "ref": "ev_linezolid_serotonin_fda2011",
          "title": "FDA Drug Safety Communication: Updated drug labels for linezolid (Zyvox) with new serious drug interaction information (2011)",
          "type": "fda_label",
          "pmid": "21416684",
          "doi": "",
          "url": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-drug-labels-linezolid-zyvox",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-drug-labels-linezolid-zyvox"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=linezolid,sertraline&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#psychiatry-neurology-linezolid-sertraline",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "linezolid-sertraline",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "psychiatry-neurology-donepezil-metoprolol",
      "label": "Donepezil + metoprolol",
      "guideId": "psychiatry-neurology",
      "guideTitle": "Psychiatry, Neurology, Sleep, and OTC Sedating Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "donepezil",
          "name": "Donepezil",
          "id": "donepezil",
          "class": "Dementia / Acetylcholinesterase Inhibitor"
        },
        {
          "input": "metoprolol",
          "name": "Metoprolol",
          "id": "metoprolol",
          "class": "Beta-blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Low blood pressure risk may increase",
      "reviewQuestion": "Can you check whether this combination could cause low blood pressure, dizziness, or fainting?",
      "patientSummary": "Low blood pressure risk may increase",
      "patientQuestion": "Can you check whether this combination could cause low blood pressure, dizziness, or fainting?",
      "clinicianSummary": "Low blood pressure risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Donepezil can have vagotonic effects on sinoatrial/atrioventricular nodes, and metoprolol also lowers heart rate.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_donepezil_bradycardia_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_donepezil_bradycardia_label",
          "title": "Donepezil prescribing information - vagotonic bradycardia and CYP3A4/2D6 metabolism",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=donepezil,metoprolol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#psychiatry-neurology-donepezil-metoprolol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "donepezil-metoprolol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "psychiatry-neurology-desmopressin-sertraline",
      "label": "Desmopressin + sertraline",
      "guideId": "psychiatry-neurology",
      "guideTitle": "Psychiatry, Neurology, Sleep, and OTC Sedating Medicines",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "desmopressin",
          "name": "Desmopressin",
          "id": "desmopressin",
          "class": "Vasopressin Analog / Hemostatic-Endocrine Agent"
        },
        {
          "input": "sertraline",
          "name": "Sertraline",
          "id": "sertraline",
          "class": "SSRI"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Sertraline exposure may rise with Desmopressin",
      "reviewQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "patientSummary": "Serotonin-related side effects may increase",
      "patientQuestion": "Can you check whether this combination raises serotonin-related side effects or switching concerns?",
      "clinicianSummary": "Sertraline exposure may rise with Desmopressin",
      "mechanismSummary": "Desmopressin may increase Sertraline exposure, raising Sertraline toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "SSRI-associated SIADH tendency can add to desmopressin water retention.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "linked source · guideline · 2 sources",
      "evidenceStatus": "guideline · 2 sources · mechanistic high · linked source",
      "evidenceRefs": [
        "ev_stroke_neurocritical_workflow"
      ],
      "evidenceSources": [
        {
          "ref": "ev_stroke_neurocritical_workflow",
          "title": "Stroke/thrombolysis/neurocritical medication workflow coverage: fibrinolysis, anticoagulant reversal, hemostasis support, seizure loading, and osmotherapy",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://www.heart.org/en/professional/quality-improvement/stroke",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://www.heart.org/en/professional/quality-improvement/stroke"
      ],
      "sourceLinked": true,
      "provenanceStatus": "linked source · guideline · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=desmopressin,sertraline&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#psychiatry-neurology-desmopressin-sertraline",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "desmopressin-sertraline",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-antiinfective-simvastatin-clarithromycin",
      "label": "Simvastatin + clarithromycin",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "simvastatin",
          "name": "Simvastatin",
          "id": "simvastatin",
          "class": "Statin"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Simvastatin exposure may rise with Clarithromycin",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Simvastatin exposure may rise with Clarithromycin",
      "mechanismSummary": "Clarithromycin may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Simvastatin, Clarithromycin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 8 sources",
      "evidenceStatus": "fda label · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_simvastatin_label_cyp3a4",
        "ev_statin_cyp3a4_williams2002",
        "ev_simvastatin_multigene_choi2016",
        "ev_statin_slco1b1_abcg2_cpic2022"
      ],
      "evidenceSources": [
        {
          "ref": "ev_simvastatin_label_cyp3a4",
          "title": "Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_statin_cyp3a4_williams2002",
          "title": "Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors",
          "type": "clinical_pk",
          "pmid": "12036392",
          "doi": "10.2165/00003088-200241050-00003",
          "url": "https://pubmed.ncbi.nlm.nih.gov/12036392/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_multigene_choi2016",
          "title": "Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid",
          "type": "rct",
          "pmid": "26367500",
          "doi": "10.1097/fpc.0000000000000176",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26367500/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_statin_slco1b1_abcg2_cpic2022",
          "title": "CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
          "type": "guideline",
          "pmid": "35152405",
          "doi": "10.1002/cpt.2557",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://pubmed.ncbi.nlm.nih.gov/12036392/",
        "https://pubmed.ncbi.nlm.nih.gov/26367500/",
        "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=simvastatin,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-antiinfective-simvastatin-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "antiinfective-simvastatin-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-antiinfective-warfarin-tmp-smx",
      "label": "Warfarin + TMP-SMX",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        },
        {
          "input": "trimethoprim_sulfamethoxazole",
          "name": "Trimethoprim/Sulfamethoxazole",
          "id": "trimethoprim_sulfamethoxazole",
          "class": "Sulfonamide Antibiotic / Folate Antagonist"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Bleeding burden may rise",
      "reviewQuestion": "Can you check whether Warfarin + Trimethoprim/Sulfamethoxazole needs closer bleeding or clotting monitoring?",
      "patientSummary": "Warfarin bleeding risk may increase",
      "patientQuestion": "Can you check whether Warfarin + Trimethoprim/Sulfamethoxazole needs closer bleeding or clotting monitoring?",
      "clinicianSummary": "Bleeding burden may rise",
      "mechanismSummary": "Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "CYP2C9 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (45% capacity). Drivers: Trimethoprim/Sulfamethoxazole inhibitor, current stack substrate burden. Affects Warfarin, Trimeth...",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tmp_smx_label",
        "ev_warfarin_abx_lane2014"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tmp_smx_label",
          "title": "Sulfamethoxazole/trimethoprim prescribing information - warfarin, OCT2/CYP2C8, and folate-toxicity context",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_warfarin_abx_lane2014",
          "title": "Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans",
          "type": "observational",
          "pmid": "24657899",
          "doi": "10.1016/j.amjmed.2014.01.044",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24657899/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://pubmed.ncbi.nlm.nih.gov/24657899/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=warfarin,trimethoprim_sulfamethoxazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-antiinfective-warfarin-tmp-smx",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "antiinfective-warfarin-tmp-smx",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-tacrolimus-voriconazole",
      "label": "Tacrolimus + voriconazole",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "tacrolimus",
          "name": "Tacrolimus",
          "id": "tacrolimus",
          "class": "Immunosuppressant"
        },
        {
          "input": "voriconazole",
          "name": "Voriconazole",
          "id": "voriconazole",
          "class": "Azole Antifungal"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Tacrolimus exposure may rise with Voriconazole",
      "reviewQuestion": "Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?",
      "patientSummary": "Tacrolimus side-effect risk may increase",
      "patientQuestion": "Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?",
      "clinicianSummary": "Tacrolimus exposure may rise with Voriconazole",
      "mechanismSummary": "Voriconazole may increase Tacrolimus exposure, raising Tacrolimus toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Voriconazole inhibitor, current stack substrate burden. Affects Tacrolimus, Voriconazole.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 11 sources",
      "evidenceStatus": "guideline · 11 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tacrolimus_voriconazole_vanhove2017",
        "ev_tacrolimus_cyp3a5_cpic",
        "ev_voriconazole_cyp2c19_hyland2008",
        "ev_tacrolimus_liver_multigene_ladd2025",
        "ev_tacrolimus_renal_dose_model_srinivas2023",
        "ev_tacrolimus_cyp3a5_consensus"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tacrolimus_voriconazole_vanhove2017",
          "title": "Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients",
          "type": "observational",
          "pmid": "28224698",
          "doi": "10.1111/ajt.14232",
          "url": "https://pubmed.ncbi.nlm.nih.gov/28224698/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_cyp3a5_cpic",
          "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing",
          "type": "guideline",
          "pmid": "25801146",
          "doi": "10.1002/cpt.113",
          "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_voriconazole_cyp2c19_hyland2008",
          "title": "Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole",
          "type": "clinical_pk",
          "pmid": "18192898",
          "doi": "10.1124/dmd.107.017392",
          "url": "https://pubmed.ncbi.nlm.nih.gov/18192898/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_liver_multigene_ladd2025",
          "title": "Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation",
          "type": "clinical_pk",
          "pmid": "40604035",
          "doi": "10.1038/s41598-025-09296-1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40604035/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_renal_dose_model_srinivas2023",
          "title": "Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients",
          "type": "clinical_pk",
          "pmid": "34916931",
          "doi": "10.3389/fphar.2021.726784",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34916931/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_cyp3a5_consensus",
          "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP3A5 Genotype and Tacrolimus Dosing",
          "type": "guideline",
          "pmid": "25813372",
          "doi": "10.1002/cpt.113",
          "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/28224698/",
        "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
        "https://pubmed.ncbi.nlm.nih.gov/18192898/",
        "https://pubmed.ncbi.nlm.nih.gov/40604035/",
        "https://pubmed.ncbi.nlm.nih.gov/34916931/",
        "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 11 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=tacrolimus,voriconazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-tacrolimus-voriconazole",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "tacrolimus-voriconazole",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-colchicine-clarithromycin",
      "label": "Colchicine + clarithromycin",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "colchicine",
          "name": "Colchicine",
          "id": "colchicine",
          "class": "Anti-gout"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Colchicine exposure may rise with Clarithromycin",
      "reviewQuestion": "Can you check whether Colchicine side effects or monitoring needs could increase?",
      "patientSummary": "Colchicine side-effect risk may increase",
      "patientQuestion": "Can you check whether Colchicine side effects or monitoring needs could increase?",
      "clinicianSummary": "Colchicine exposure may rise with Clarithromycin",
      "mechanismSummary": "Clarithromycin may increase Colchicine exposure, raising Colchicine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Colchicine, Clarithromycin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 7 sources",
      "evidenceStatus": "fda label · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_colchicine_clarithromycin_hung2005",
        "ev_colchicine_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_colchicine_clarithromycin_hung2005",
          "title": "Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study",
          "type": "observational",
          "pmid": "16007523",
          "doi": "10.1086/431592",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16007523/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_colchicine_label",
          "title": "Colchicine (Colcrys) Prescribing Information — CYP3A4 and P-glycoprotein inhibitors",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/16007523/",
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=colchicine,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-colchicine-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "colchicine-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-tizanidine-ciprofloxacin",
      "label": "Tizanidine + ciprofloxacin",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "tizanidine",
          "name": "Tizanidine",
          "id": "tizanidine",
          "class": "Muscle Relaxant"
        },
        {
          "input": "ciprofloxacin",
          "name": "Ciprofloxacin",
          "id": "ciprofloxacin",
          "class": "Fluoroquinolone"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "CNS depression burden may rise",
      "reviewQuestion": "Can you check whether this list raises confusion, constipation, urination, or fall risk?",
      "patientSummary": "Sleepiness, breathing, or fall risk may increase",
      "patientQuestion": "Can you check whether this list raises confusion, constipation, urination, or fall risk?",
      "clinicianSummary": "CNS depression burden may rise",
      "mechanismSummary": "CNS depression burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "CYP1A2 genetic phenotype is normal metabolizer; functional phenotype is poor function (20% capacity). Drivers: Ciprofloxacin inhibitor. Affects Tizanidine, Ciprofloxacin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 4 sources",
      "evidenceStatus": "fda label · 4 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tizanidine_ciprofloxacin_fda"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tizanidine_ciprofloxacin_fda",
          "title": "Tizanidine prescribing information - ciprofloxacin interaction",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 4 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=tizanidine,ciprofloxacin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-tizanidine-ciprofloxacin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "tizanidine-ciprofloxacin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-dofetilide-tmp-smx",
      "label": "Dofetilide + TMP-SMX",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "dofetilide",
          "name": "Dofetilide",
          "id": "dofetilide",
          "class": "Class III Antiarrhythmic"
        },
        {
          "input": "trimethoprim_sulfamethoxazole",
          "name": "Trimethoprim/Sulfamethoxazole",
          "id": "trimethoprim_sulfamethoxazole",
          "class": "Sulfonamide Antibiotic / Folate Antagonist"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Trimethoprim/Sulfamethoxazole exposure may rise with Dofetilide",
      "reviewQuestion": "Can you check whether Trimethoprim/Sulfamethoxazole side effects or monitoring needs could increase?",
      "patientSummary": "Trimethoprim/Sulfamethoxazole side-effect risk may increase",
      "patientQuestion": "Can you check whether Trimethoprim/Sulfamethoxazole side effects or monitoring needs could increase?",
      "clinicianSummary": "Trimethoprim/Sulfamethoxazole exposure may rise with Dofetilide",
      "mechanismSummary": "Dofetilide may increase Trimethoprim/Sulfamethoxazole exposure, raising Trimethoprim/Sulfamethoxazole toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Trimethoprim inhibits renal cation secretion involved in dofetilide elimination.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_dofetilide_renal_cation_label",
        "ev_tmp_smx_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_dofetilide_renal_cation_label",
          "title": "Dofetilide prescribing information - renal cation transport contraindications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_tmp_smx_label",
          "title": "Sulfamethoxazole/trimethoprim prescribing information - warfarin, OCT2/CYP2C8, and folate-toxicity context",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=dofetilide,trimethoprim_sulfamethoxazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-dofetilide-tmp-smx",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "dofetilide-tmp-smx",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-antiinfective-nirmatrelvir-ritonavir-simvastatin",
      "label": "Nirmatrelvir/ritonavir + simvastatin",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "nirmatrelvir_ritonavir",
          "name": "Nirmatrelvir/Ritonavir",
          "id": "nirmatrelvir_ritonavir",
          "class": "COVID-19 Antiviral / CYP3A Booster"
        },
        {
          "input": "simvastatin",
          "name": "Simvastatin",
          "id": "simvastatin",
          "class": "Statin"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Simvastatin exposure may rise with Nirmatrelvir/Ritonavir",
      "reviewQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "patientSummary": "Muscle injury risk may increase",
      "patientQuestion": "Can you check whether this combination could raise muscle pain or muscle injury risk?",
      "clinicianSummary": "Simvastatin exposure may rise with Nirmatrelvir/Ritonavir",
      "mechanismSummary": "Nirmatrelvir/Ritonavir may increase Simvastatin exposure, raising Simvastatin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Nirmatrelvir/Ritonavir inhibitor, current stack substrate burden. Affects Nirmatrelvir/Ritonavir, Simvasta...",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 8 sources",
      "evidenceStatus": "fda label · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_paxlovid_cyp3a_label",
        "ev_simvastatin_multigene_choi2016",
        "ev_simvastatin_label_cyp3a4",
        "ev_statin_slco1b1_abcg2_cpic2022"
      ],
      "evidenceSources": [
        {
          "ref": "ev_paxlovid_cyp3a_label",
          "title": "Paxlovid prescribing information - CYP3A inhibition and strong inducer contraindications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_multigene_choi2016",
          "title": "Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid",
          "type": "rct",
          "pmid": "26367500",
          "doi": "10.1097/fpc.0000000000000176",
          "url": "https://pubmed.ncbi.nlm.nih.gov/26367500/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_simvastatin_label_cyp3a4",
          "title": "Simvastatin (Zocor) Prescribing Information — Contraindicated and dose-limited interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_statin_slco1b1_abcg2_cpic2022",
          "title": "CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms",
          "type": "guideline",
          "pmid": "35152405",
          "doi": "10.1002/cpt.2557",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a",
        "https://pubmed.ncbi.nlm.nih.gov/26367500/",
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=nirmatrelvir_ritonavir,simvastatin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-antiinfective-nirmatrelvir-ritonavir-simvastatin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "antiinfective-nirmatrelvir-ritonavir-simvastatin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "infectious-disease-darunavir-rifampin",
      "label": "Darunavir + rifampin",
      "guideId": "infectious-disease",
      "guideTitle": "Antibiotics, Antifungals, and Antivirals",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "darunavir",
          "name": "Darunavir",
          "id": "darunavir",
          "class": "HIV Protease Inhibitor"
        },
        {
          "input": "rifampin",
          "name": "Rifampin",
          "id": "rifampin",
          "class": "Rifamycin"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Darunavir exposure may rise with Rifampin",
      "reviewQuestion": "Can you check whether Darunavir side effects or monitoring needs could increase?",
      "patientSummary": "Darunavir may work less well",
      "patientQuestion": "Can you check whether Darunavir side effects or monitoring needs could increase?",
      "clinicianSummary": "Darunavir exposure may rise with Rifampin",
      "mechanismSummary": "Rifampin may increase Darunavir exposure, raising Darunavir toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Rifampin strongly induces CYP3A/P-gp and can sharply reduce boosted darunavir exposure.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_darunavir_boosted_cyp3a_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_darunavir_boosted_cyp3a_label",
          "title": "Darunavir prescribing information - boosted CYP3A interaction liability",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=darunavir%20rifampin%20simvastatin%20midazolam",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=darunavir%20rifampin%20simvastatin%20midazolam"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=darunavir,rifampin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#infectious-disease-darunavir-rifampin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "darunavir-rifampin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-gi-clopidogrel-omeprazole-cyp2c19-pm",
      "label": "Clopidogrel + omeprazole with CYP2C19 PM",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "clopidogrel",
          "name": "Clopidogrel",
          "id": "clopidogrel",
          "class": "Antiplatelet"
        },
        {
          "input": "omeprazole",
          "name": "Omeprazole",
          "id": "omeprazole",
          "class": "PPI"
        }
      ],
      "genotypes": [
        "CYP2C19:PM"
      ],
      "severity": "critical",
      "priority": "critical",
      "summary": "Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole",
      "reviewQuestion": "Can you check whether Clopidogrel may work less well with my current list?",
      "patientSummary": "Clopidogrel may work less well with Omeprazole",
      "patientQuestion": "Can you check whether Clopidogrel may work less well with my current list?",
      "clinicianSummary": "Clopidogrel activation to Active thiol metabolite may be reduced with Omeprazole",
      "mechanismSummary": "Increased stent thrombosis and MI risk. FDA warning Additional grouped signal: Clopidogrel exposure may fall with Omeprazole; CYP2C19 behaves as poor function. Related genotype, pathway, and metabolite signals are grouped below.",
      "clinicalRationale": "CYP2C19 genetic phenotype is poor metabolizer; functional phenotype is poor function (15% capacity). Drivers: CYP2C19 genotype, Omeprazole inhibitor, current stack substrate burden. Affects Clopidogrel, Omeprazole.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · rct · 7 sources",
      "evidenceStatus": "rct · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_clopidogrel_cyp2c19_cpic",
        "ev_omeprazole_cyp2c19_lima2021",
        "ev_clopidogrel_active_thiol_kim2014",
        "ev_clopidogrel_cyp2c19_mega2009",
        "ev_clopidogrel_dose_escalation_horenstein2014"
      ],
      "evidenceSources": [
        {
          "ref": "ev_clopidogrel_cyp2c19_cpic",
          "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update",
          "type": "guideline",
          "pmid": "35034351",
          "doi": "10.1002/cpt.2526",
          "url": "https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351.pdf",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_omeprazole_cyp2c19_lima2021",
          "title": "CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing",
          "type": "guideline",
          "pmid": "32770672",
          "doi": "10.1002/cpt.1168",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32770672/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        },
        {
          "ref": "ev_clopidogrel_active_thiol_kim2014",
          "title": "CYP2C19 phenotype effect on clopidogrel active thiol metabolite exposure and platelet inhibition",
          "type": "clinical_pk",
          "pmid": "25196410",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25196410/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_clopidogrel_cyp2c19_mega2009",
          "title": "Cytochrome P-450 polymorphisms and response to clopidogrel",
          "type": "rct",
          "pmid": "19106084",
          "doi": "10.1056/NEJMoa0809171",
          "url": "https://pubmed.ncbi.nlm.nih.gov/19106084/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_clopidogrel_dose_escalation_horenstein2014",
          "title": "Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers",
          "type": "clinical_pk",
          "pmid": "24710841",
          "doi": "10.1002/jcph.293",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24710841/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351.pdf",
        "https://pubmed.ncbi.nlm.nih.gov/32770672/",
        "https://pubmed.ncbi.nlm.nih.gov/25196410/",
        "https://pubmed.ncbi.nlm.nih.gov/19106084/",
        "https://pubmed.ncbi.nlm.nih.gov/24710841/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · rct · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=clopidogrel,omeprazole&genotype=CYP2C19:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-gi-clopidogrel-omeprazole-cyp2c19-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "gi-clopidogrel-omeprazole-cyp2c19-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-erlotinib-omeprazole",
      "label": "Erlotinib + omeprazole",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "erlotinib",
          "name": "Erlotinib",
          "id": "erlotinib",
          "class": "EGFR Tyrosine Kinase Inhibitor"
        },
        {
          "input": "omeprazole",
          "name": "Omeprazole",
          "id": "omeprazole",
          "class": "PPI"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Erlotinib absorption may fall with Omeprazole",
      "reviewQuestion": "Can you check whether Erlotinib may not absorb as expected with my current list?",
      "patientSummary": "Erlotinib may not absorb as expected",
      "patientQuestion": "Can you check whether Erlotinib may not absorb as expected with my current list?",
      "clinicianSummary": "Erlotinib absorption may fall with Omeprazole",
      "mechanismSummary": "↓↓ Marked 46% reduction in erlotinib systemic bio-availability, risking premature oncology therapeutic failure. Additional grouped signal: CYP3A4 behaves as intermediate function.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (72% capacity). Drivers: Erlotinib inhibitor, current stack substrate burden. Affects Erlotinib, Omeprazole.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "primary-literature linked · observational · 5 sources",
      "evidenceStatus": "observational · 5 sources · mechanistic moderate · primary-literature linked",
      "evidenceRefs": [
        "ev_erlotinib_ppi_absorption"
      ],
      "evidenceSources": [
        {
          "ref": "ev_erlotinib_ppi_absorption",
          "title": "Effect of Proton Pump Inhibitors on the Pharmacokinetics of Erlotinib in Non-Small Cell Lung Cancer",
          "type": "observational",
          "pmid": "31045210",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31045210/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/31045210/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · observational · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=erlotinib,omeprazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-erlotinib-omeprazole",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "erlotinib-omeprazole",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-erlotinib-famotidine",
      "label": "Erlotinib + famotidine",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "erlotinib",
          "name": "Erlotinib",
          "id": "erlotinib",
          "class": "EGFR Tyrosine Kinase Inhibitor"
        },
        {
          "input": "famotidine",
          "name": "Famotidine",
          "id": "famotidine",
          "class": "H2 Blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Erlotinib absorption may fall with Famotidine",
      "reviewQuestion": "Can you check whether Erlotinib may not absorb as expected with my current list?",
      "patientSummary": "Erlotinib may not absorb as expected",
      "patientQuestion": "Can you check whether Erlotinib may not absorb as expected with my current list?",
      "clinicianSummary": "Erlotinib absorption may fall with Famotidine",
      "mechanismSummary": "Reduced EGFR TKI exposure; use label timing strategy or avoid chronic acid suppression when possible.",
      "clinicalRationale": "H2 antagonists raise gastric pH and decrease erlotinib plasma concentrations unless label timing separation is used.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "primary-literature linked · observational · 1 source",
      "evidenceStatus": "observational · 1 source · mechanistic moderate · primary-literature linked",
      "evidenceRefs": [
        "ev_erlotinib_ppi_absorption"
      ],
      "evidenceSources": [
        {
          "ref": "ev_erlotinib_ppi_absorption",
          "title": "Effect of Proton Pump Inhibitors on the Pharmacokinetics of Erlotinib in Non-Small Cell Lung Cancer",
          "type": "observational",
          "pmid": "31045210",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/31045210/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/31045210/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · observational · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=erlotinib,famotidine&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-erlotinib-famotidine",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "erlotinib-famotidine",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-levothyroxine-iron",
      "label": "Levothyroxine + iron",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "levothyroxine",
          "name": "Levothyroxine",
          "id": "levothyroxine",
          "class": "Thyroid"
        },
        {
          "input": "iron",
          "name": "Iron",
          "id": "iron",
          "class": "Supplement"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Levothyroxine absorption may fall with Iron",
      "reviewQuestion": "Can you check whether Levothyroxine may not absorb as expected with my current list?",
      "patientSummary": "Levothyroxine may not absorb as expected",
      "patientQuestion": "Can you check whether Levothyroxine may not absorb as expected with my current list?",
      "clinicianSummary": "Levothyroxine absorption may fall with Iron",
      "mechanismSummary": "Reduced levothyroxine exposure; separate administration and monitor thyroid response after chronic iron use.",
      "clinicalRationale": "Iron forms insoluble complexes with levothyroxine and reduces absorption.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_levothyroxine_absorption_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_levothyroxine_absorption_label",
          "title": "Levothyroxine prescribing information - absorption reduced by binding agents, minerals, and acid suppression context",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=levothyroxine",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=levothyroxine"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=levothyroxine,iron&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-levothyroxine-iron",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "levothyroxine-iron",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-levothyroxine-calcium",
      "label": "Levothyroxine + calcium",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "levothyroxine",
          "name": "Levothyroxine",
          "id": "levothyroxine",
          "class": "Thyroid"
        },
        {
          "input": "calcium",
          "name": "Calcium",
          "id": "calcium",
          "class": "Supplement"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Levothyroxine absorption may fall with Calcium",
      "reviewQuestion": "Can you check whether Levothyroxine may not absorb as expected with my current list?",
      "patientSummary": "Levothyroxine may not absorb as expected",
      "patientQuestion": "Can you check whether Levothyroxine may not absorb as expected with my current list?",
      "clinicianSummary": "Levothyroxine absorption may fall with Calcium",
      "mechanismSummary": "Reduced levothyroxine exposure and possible hypothyroid breakthrough; separate administration and monitor TSH after chronic changes.",
      "clinicalRationale": "Calcium binds levothyroxine in the GI tract, reducing absorption.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_levothyroxine_absorption_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_levothyroxine_absorption_label",
          "title": "Levothyroxine prescribing information - absorption reduced by binding agents, minerals, and acid suppression context",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=levothyroxine",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=levothyroxine"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=levothyroxine,calcium&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-levothyroxine-calcium",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "levothyroxine-calcium",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-ciprofloxacin-iron",
      "label": "Ciprofloxacin + iron",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ciprofloxacin",
          "name": "Ciprofloxacin",
          "id": "ciprofloxacin",
          "class": "Fluoroquinolone"
        },
        {
          "input": "iron",
          "name": "Iron",
          "id": "iron",
          "class": "Supplement"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Ciprofloxacin absorption may fall with Iron",
      "reviewQuestion": "Can you check whether Ciprofloxacin may not absorb as expected with my current list?",
      "patientSummary": "Ciprofloxacin may not absorb as expected",
      "patientQuestion": "Can you check whether Ciprofloxacin may not absorb as expected with my current list?",
      "clinicianSummary": "Ciprofloxacin absorption may fall with Iron",
      "mechanismSummary": "Reduced antibiotic exposure; separate ciprofloxacin from iron-containing products.",
      "clinicalRationale": "Iron chelates ciprofloxacin in the GI tract and reduces absorption.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_fluoroquinolone_cation_absorption_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_fluoroquinolone_cation_absorption_label",
          "title": "Fluoroquinolone prescribing information - multivalent cation chelation lowers oral absorption",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=ciprofloxacin%20levofloxacin%20moxifloxacin%20multivalent%20cations",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=ciprofloxacin%20levofloxacin%20moxifloxacin%20multivalent%20cations"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ciprofloxacin,iron&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-ciprofloxacin-iron",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ciprofloxacin-iron",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-doxycycline-calcium",
      "label": "Doxycycline + calcium",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "doxycycline",
          "name": "Doxycycline",
          "id": "doxycycline",
          "class": "Tetracycline"
        },
        {
          "input": "calcium",
          "name": "Calcium",
          "id": "calcium",
          "class": "Supplement"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Doxycycline absorption may fall with Calcium",
      "reviewQuestion": "Can you check whether Doxycycline may not absorb as expected with my current list?",
      "patientSummary": "Doxycycline may not absorb as expected",
      "patientQuestion": "Can you check whether Doxycycline may not absorb as expected with my current list?",
      "clinicianSummary": "Doxycycline absorption may fall with Calcium",
      "mechanismSummary": "Reduced doxycycline exposure and possible treatment failure; separate dosing from calcium products.",
      "clinicalRationale": "Calcium-containing antacids/minerals impair tetracycline absorption through chelation.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tetracycline_cation_absorption_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tetracycline_cation_absorption_label",
          "title": "Tetracycline-class prescribing information - antacids, calcium, and iron impair absorption",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=doxycycline%20antacids%20iron%20calcium",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=doxycycline%20antacids%20iron%20calcium"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=doxycycline,calcium&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-doxycycline-calcium",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "doxycycline-calcium",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "acid-suppression-gi-minerals-bictegravir-iron",
      "label": "Bictegravir + iron",
      "guideId": "acid-suppression-gi-minerals",
      "guideTitle": "Acid Suppression, GI, Minerals, and Binding Interactions",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "bictegravir",
          "name": "Bictegravir",
          "id": "bictegravir",
          "class": "HIV Integrase Inhibitor"
        },
        {
          "input": "iron",
          "name": "Iron",
          "id": "iron",
          "class": "Supplement"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Iron absorption may fall with Bictegravir",
      "reviewQuestion": "Can you check whether Iron may not absorb as expected with my current list?",
      "patientSummary": "Iron may not absorb as expected",
      "patientQuestion": "Can you check whether Iron may not absorb as expected with my current list?",
      "clinicianSummary": "Iron absorption may fall with Bictegravir",
      "mechanismSummary": "Use label timing/food strategy; treatment failure risk matters when mineral use is chronic.",
      "clinicalRationale": "Iron can chelate bictegravir and lower absorption if taken together incorrectly.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_bictegravir_cation_induction_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_bictegravir_cation_induction_label",
          "title": "Bictegravir/FTC/TAF prescribing information - polyvalent cations and strong induction",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=biktarvy%20bictegravir%20calcium%20iron%20rifampin",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=biktarvy%20bictegravir%20calcium%20iron%20rifampin"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=bictegravir,iron&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#acid-suppression-gi-minerals-bictegravir-iron",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "bictegravir-iron",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-combined-oral-contraceptive-rifampin",
      "label": "Combined oral contraceptive + rifampin",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "combined_oral_contraceptive",
          "name": "Combined Oral Contraceptive",
          "id": "combined_oral_contraceptive",
          "class": "Estrogen/Progestin Contraceptive"
        },
        {
          "input": "rifampin",
          "name": "Rifampin",
          "id": "rifampin",
          "class": "Rifamycin"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Rifampin exposure may rise with Combined Oral Contraceptive",
      "reviewQuestion": "Can you check whether Rifampin side effects or monitoring needs could increase?",
      "patientSummary": "Rifampin may work less well",
      "patientQuestion": "Can you check whether Rifampin side effects or monitoring needs could increase?",
      "clinicianSummary": "Rifampin exposure may rise with Combined Oral Contraceptive",
      "mechanismSummary": "Combined Oral Contraceptive may increase Rifampin exposure, raising Rifampin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Rifampin strongly induces drug-metabolizing enzymes and can reduce estrogen/progestin exposure.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_coc_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_coc_label",
          "title": "Combined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=combined_oral_contraceptive,rifampin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-combined-oral-contraceptive-rifampin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "combined-oral-contraceptive-rifampin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-combined-oral-contraceptive-carbamazepine",
      "label": "Combined oral contraceptive + carbamazepine",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "combined_oral_contraceptive",
          "name": "Combined Oral Contraceptive",
          "id": "combined_oral_contraceptive",
          "class": "Estrogen/Progestin Contraceptive"
        },
        {
          "input": "carbamazepine",
          "name": "Carbamazepine",
          "id": "carbamazepine",
          "class": "Anticonvulsant"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Carbamazepine exposure may rise with Combined Oral Contraceptive",
      "reviewQuestion": "Can you check whether Carbamazepine side effects or monitoring needs could increase?",
      "patientSummary": "Carbamazepine may work less well",
      "patientQuestion": "Can you check whether Carbamazepine side effects or monitoring needs could increase?",
      "clinicianSummary": "Carbamazepine exposure may rise with Combined Oral Contraceptive",
      "mechanismSummary": "Combined Oral Contraceptive may increase Carbamazepine exposure, raising Carbamazepine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is increased function (600% capacity). Drivers: Carbamazepine inducer, current stack substrate burden. Affects Combined Oral Contraceptive, Carbamaz...",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 4 sources",
      "evidenceStatus": "fda label · 4 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_coc_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_coc_label",
          "title": "Combined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 4 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=combined_oral_contraceptive,carbamazepine&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-combined-oral-contraceptive-carbamazepine",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "combined-oral-contraceptive-carbamazepine",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-combined-oral-contraceptive-lamotrigine",
      "label": "Combined oral contraceptive + lamotrigine",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "combined_oral_contraceptive",
          "name": "Combined Oral Contraceptive",
          "id": "combined_oral_contraceptive",
          "class": "Estrogen/Progestin Contraceptive"
        },
        {
          "input": "lamotrigine",
          "name": "Lamotrigine",
          "id": "lamotrigine",
          "class": "Anticonvulsant"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Lamotrigine exposure may fall with Combined Oral Contraceptive",
      "reviewQuestion": "Can you check whether Lamotrigine may work less well with my current list?",
      "patientSummary": "Lamotrigine may work less well",
      "patientQuestion": "Can you check whether Lamotrigine may work less well with my current list?",
      "clinicianSummary": "Lamotrigine exposure may fall with Combined Oral Contraceptive",
      "mechanismSummary": "Combined Oral Contraceptive may reduce Lamotrigine exposure or effect. Related pathway and timing signals are grouped below.",
      "clinicalRationale": "Ethinyl estradiol-containing contraceptives induce lamotrigine glucuronidation and can reduce lamotrigine exposure by about half.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_coc_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_coc_label",
          "title": "Combined oral contraceptive prescribing information - enzyme induction and lamotrigine interaction",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=combined_oral_contraceptive,lamotrigine&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-combined-oral-contraceptive-lamotrigine",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "combined-oral-contraceptive-lamotrigine",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-ethinyl-estradiol-rifampin",
      "label": "Ethinyl estradiol + rifampin",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ethinyl_estradiol",
          "name": "Ethinyl Estradiol",
          "id": "ethinyl_estradiol",
          "class": "Synthetic Estrogen / Contraceptive Component"
        },
        {
          "input": "rifampin",
          "name": "Rifampin",
          "id": "rifampin",
          "class": "Rifamycin"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Rifampin exposure may fall with Ethinyl Estradiol",
      "reviewQuestion": "Can you check whether Rifampin may work less well with my current list?",
      "patientSummary": "Rifampin may work less well",
      "patientQuestion": "Can you check whether Rifampin may work less well with my current list?",
      "clinicianSummary": "Rifampin exposure may fall with Ethinyl Estradiol",
      "mechanismSummary": "Ethinyl Estradiol may reduce Rifampin exposure or effect. Related pathway and timing signals are grouped below.",
      "clinicalRationale": "Rifampin strongly induces CYP3A4 and UGT pathways, lowering estrogen/progestin contraceptive exposure.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "linked source · guideline · 1 source",
      "evidenceStatus": "guideline · 1 source · mechanistic high · linked source",
      "evidenceRefs": [
        "ev_rifampin_hormonal_contraception"
      ],
      "evidenceSources": [
        {
          "ref": "ev_rifampin_hormonal_contraception",
          "title": "Rifampin and hormonal contraceptive efficacy guidance",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://www.cdc.gov/contraception/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://www.cdc.gov/contraception/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "linked source · guideline · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ethinyl_estradiol,rifampin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-ethinyl-estradiol-rifampin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ethinyl-estradiol-rifampin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-ethinyl-estradiol-lamotrigine",
      "label": "Ethinyl estradiol + lamotrigine",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ethinyl_estradiol",
          "name": "Ethinyl Estradiol",
          "id": "ethinyl_estradiol",
          "class": "Synthetic Estrogen / Contraceptive Component"
        },
        {
          "input": "lamotrigine",
          "name": "Lamotrigine",
          "id": "lamotrigine",
          "class": "Anticonvulsant"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Lamotrigine exposure may fall with Ethinyl Estradiol",
      "reviewQuestion": "Can you check whether Lamotrigine may work less well with my current list?",
      "patientSummary": "Lamotrigine may work less well",
      "patientQuestion": "Can you check whether Lamotrigine may work less well with my current list?",
      "clinicianSummary": "Lamotrigine exposure may fall with Ethinyl Estradiol",
      "mechanismSummary": "Ethinyl Estradiol may reduce Lamotrigine exposure or effect. Related pathway and timing signals are grouped below.",
      "clinicalRationale": "Ethinyl estradiol induces lamotrigine glucuronidation.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "primary-literature linked · clinical pk · 1 source",
      "evidenceStatus": "clinical pk · 1 source · mechanistic high · primary-literature linked",
      "evidenceRefs": [
        "ev_estradiol_lamotrigine_ugt1a4"
      ],
      "evidenceSources": [
        {
          "ref": "ev_estradiol_lamotrigine_ugt1a4",
          "title": "Ethinyl estradiol-containing contraceptives induce lamotrigine glucuronidation",
          "type": "clinical_pk",
          "pmid": "16146436",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16146436/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/16146436/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · clinical pk · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ethinyl_estradiol,lamotrigine&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-ethinyl-estradiol-lamotrigine",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ethinyl-estradiol-lamotrigine",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-levonorgestrel-efavirenz",
      "label": "Levonorgestrel + efavirenz",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "levonorgestrel",
          "name": "Levonorgestrel",
          "id": "levonorgestrel",
          "class": "Progestin / Contraceptive Component"
        },
        {
          "input": "efavirenz",
          "name": "Efavirenz",
          "id": "efavirenz",
          "class": "Antiretroviral"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Levonorgestrel exposure may fall with Efavirenz",
      "reviewQuestion": "Can you check whether Levonorgestrel may work less well with my current list?",
      "patientSummary": "Levonorgestrel may work less well",
      "patientQuestion": "Can you check whether Levonorgestrel may work less well with my current list?",
      "clinicianSummary": "Levonorgestrel exposure may fall with Efavirenz",
      "mechanismSummary": "Efavirenz may reduce Levonorgestrel exposure or effect. Related pathway and timing signals are grouped below.",
      "clinicalRationale": "Efavirenz induces CYP3A4 and can lower levonorgestrel exposure.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "primary-literature linked · clinical pk · 1 source",
      "evidenceStatus": "clinical pk · 1 source · mechanistic high · primary-literature linked",
      "evidenceRefs": [
        "ev_efavirenz_levonorgestrel_contraception"
      ],
      "evidenceSources": [
        {
          "ref": "ev_efavirenz_levonorgestrel_contraception",
          "title": "Efavirenz interaction with levonorgestrel-containing contraception",
          "type": "clinical_pk",
          "pmid": "25393993",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/25393993/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/25393993/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · clinical pk · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=levonorgestrel,efavirenz&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-levonorgestrel-efavirenz",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "levonorgestrel-efavirenz",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-sugammadex-ethinyl-estradiol",
      "label": "Sugammadex + ethinyl estradiol",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "sugammadex",
          "name": "Sugammadex",
          "id": "sugammadex",
          "class": "Selective Relaxant Binding Agent"
        },
        {
          "input": "ethinyl_estradiol",
          "name": "Ethinyl Estradiol",
          "id": "ethinyl_estradiol",
          "class": "Synthetic Estrogen / Contraceptive Component"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Sugammadex absorption may fall with Ethinyl Estradiol",
      "reviewQuestion": "Can you check whether Sugammadex may not absorb as expected with my current list?",
      "patientSummary": "Sugammadex may not absorb as expected",
      "patientQuestion": "Can you check whether Sugammadex may not absorb as expected with my current list?",
      "clinicianSummary": "Sugammadex absorption may fall with Ethinyl Estradiol",
      "mechanismSummary": "Use backup contraception for 7 days after sugammadex exposure.",
      "clinicalRationale": "Sugammadex can reduce hormonal contraceptive exposure via steroid binding.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_sugammadex_contraception_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_sugammadex_contraception_label",
          "title": "Bridion (sugammadex) prescribing information — hormonal contraceptive warning",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sugammadex",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sugammadex"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=sugammadex,ethinyl_estradiol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-sugammadex-ethinyl-estradiol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "sugammadex-ethinyl-estradiol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "contraception-hormones-pregnancy-warfarin",
      "label": "Pregnancy / trying to conceive + warfarin",
      "guideId": "contraception-hormones",
      "guideTitle": "Contraception, Hormones, and Reproductive Health",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "pregnancy_trying_to_conceive",
          "name": "Pregnancy / Trying to Conceive",
          "id": "pregnancy_trying_to_conceive",
          "class": "Clinical Context / Pregnancy"
        },
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Bleeding burden may rise",
      "reviewQuestion": "Can you check whether Warfarin + Pregnancy / Trying to Conceive needs closer bleeding or clotting monitoring?",
      "patientSummary": "Warfarin bleeding risk may increase",
      "patientQuestion": "Can you check whether Warfarin + Pregnancy / Trying to Conceive needs closer bleeding or clotting monitoring?",
      "clinicianSummary": "Bleeding burden may rise",
      "mechanismSummary": "Bleeding burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "Warfarin crosses the placenta and can cause fetal bleeding and warfarin embryopathy, with risk depending on timing/dose.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 2 sources",
      "evidenceStatus": "guideline · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_pregnancy_obstetric_workflow",
        "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017"
      ],
      "evidenceSources": [
        {
          "ref": "ev_pregnancy_obstetric_workflow",
          "title": "Pregnancy and obstetric emergency medication workflow coverage: teratogenic exposure flags, hypertensive emergency, magnesium, uterotonics, hemorrhage, Rh prophylaxis, and vaccine timing",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://www.acog.org/clinical",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        },
        {
          "ref": "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017",
          "title": "CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update",
          "type": "guideline",
          "pmid": "28198005",
          "doi": "10.1002/cpt.668",
          "url": "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://www.acog.org/clinical",
        "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=pregnancy_trying_to_conceive,warfarin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#contraception-hormones-pregnancy-warfarin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "pregnancy-warfarin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-flecainide-fluoxetine-cyp2d6-pm",
      "label": "Flecainide + fluoxetine with CYP2D6 PM",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "flecainide",
          "name": "Flecainide",
          "id": "flecainide",
          "class": "Class IC Antiarrhythmic"
        },
        {
          "input": "fluoxetine",
          "name": "Fluoxetine",
          "id": "fluoxetine",
          "class": "SSRI"
        }
      ],
      "genotypes": [
        "CYP2D6:PM"
      ],
      "severity": "severe",
      "priority": "severe",
      "summary": "Flecainide exposure may rise with Fluoxetine",
      "reviewQuestion": "Can you check whether Flecainide side effects or monitoring needs could increase?",
      "patientSummary": "Flecainide side-effect risk may increase",
      "patientQuestion": "Can you check whether Flecainide side effects or monitoring needs could increase?",
      "clinicianSummary": "Flecainide exposure may rise with Fluoxetine",
      "mechanismSummary": "Fluoxetine may increase Flecainide exposure, raising Flecainide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP2D6 genetic phenotype is poor metabolizer; functional phenotype is minimal/no function (3% capacity). Drivers: CYP2D6 genotype, Fluoxetine inhibitor, current stack substrate burden. Affects Flecainide, Fluoxetine.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 8 sources",
      "evidenceStatus": "fda label · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_flecainide_cyp2d6_pgx",
        "ev_flecainide_cyp2d6_safety",
        "ev_fluoxetine_cyp2d6_fda",
        "ev_fluoxetine_cyp2d6_sunkara2010"
      ],
      "evidenceSources": [
        {
          "ref": "ev_flecainide_cyp2d6_pgx",
          "title": "Flecainide prescribing information — CYP2D6 metabolism and interaction with CYP2D6 inhibitors",
          "type": "fda_label",
          "pmid": "9626731",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_flecainide_cyp2d6_safety",
          "title": "Flecainide toxicity risks driven by CYP2D6 Poor Metabolizer status and Renal Insufficiency",
          "type": "observational",
          "pmid": "29325010",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/29325010/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_fluoxetine_cyp2d6_fda",
          "title": "Prozac (fluoxetine) Prescribing Information — Drug Interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7a4db7f-cdac-2b36-e053-2995a90a8d64",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_fluoxetine_cyp2d6_sunkara2010",
          "title": "Stereoselective pharmacokinetics of fluoxetine and norfluoxetine in CYP2D6 poor and extensive metabolizers",
          "type": "clinical_pk",
          "pmid": "20184222",
          "doi": "10.1002/jcph.39",
          "url": "https://pubmed.ncbi.nlm.nih.gov/20184222/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://pubmed.ncbi.nlm.nih.gov/29325010/",
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7a4db7f-cdac-2b36-e053-2995a90a8d64",
        "https://pubmed.ncbi.nlm.nih.gov/20184222/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=flecainide,fluoxetine&genotype=CYP2D6:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-flecainide-fluoxetine-cyp2d6-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "flecainide-fluoxetine-cyp2d6-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-cardiology-amiodarone-warfarin",
      "label": "Amiodarone + warfarin",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "amiodarone",
          "name": "Amiodarone",
          "id": "amiodarone",
          "class": "Antiarrhythmic"
        },
        {
          "input": "warfarin",
          "name": "Warfarin",
          "id": "warfarin",
          "class": "Anticoagulant"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Warfarin INR sensitivity may increase",
      "reviewQuestion": "Can you check whether Warfarin side effects or monitoring needs could increase?",
      "patientSummary": "Warfarin side-effect risk may increase",
      "patientQuestion": "Can you check whether Warfarin side effects or monitoring needs could increase?",
      "clinicianSummary": "Warfarin INR sensitivity may increase",
      "mechanismSummary": "Amiodarone may increase Warfarin exposure, raising Warfarin toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (50% capacity). Drivers: Amiodarone inhibitor. Affects Amiodarone, Warfarin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 7 sources",
      "evidenceStatus": "guideline · 7 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_amiodarone_warfarin_kerin1988",
        "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017"
      ],
      "evidenceSources": [
        {
          "ref": "ev_amiodarone_warfarin_kerin1988",
          "title": "The incidence, magnitude, and time course of the amiodarone-warfarin interaction",
          "type": "clinical_pk",
          "pmid": "3401099",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/3401099/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_warfarin_cyp2c9_vkorc1_cyp4f2_cpic2017",
          "title": "CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update",
          "type": "guideline",
          "pmid": "28198005",
          "doi": "10.1002/cpt.668",
          "url": "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/3401099/",
        "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 7 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=amiodarone,warfarin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-cardiology-amiodarone-warfarin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "cardiology-amiodarone-warfarin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-dofetilide-hydrochlorothiazide",
      "label": "Dofetilide + hydrochlorothiazide",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "dofetilide",
          "name": "Dofetilide",
          "id": "dofetilide",
          "class": "Class III Antiarrhythmic"
        },
        {
          "input": "hydrochlorothiazide",
          "name": "Hydrochlorothiazide",
          "id": "hydrochlorothiazide",
          "class": "Thiazide"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Dofetilide exposure may rise with Hydrochlorothiazide",
      "reviewQuestion": "Can you check whether Dofetilide side effects or monitoring needs could increase?",
      "patientSummary": "Dofetilide side-effect risk may increase",
      "patientQuestion": "Can you check whether Dofetilide side effects or monitoring needs could increase?",
      "clinicianSummary": "Dofetilide exposure may rise with Hydrochlorothiazide",
      "mechanismSummary": "Hydrochlorothiazide may increase Dofetilide exposure, raising Dofetilide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Hydrochlorothiazide increases dofetilide plasma concentrations and QT interval effect.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_dofetilide_renal_cation_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_dofetilide_renal_cation_label",
          "title": "Dofetilide prescribing information - renal cation transport contraindications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=dofetilide,hydrochlorothiazide&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-dofetilide-hydrochlorothiazide",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "dofetilide-hydrochlorothiazide",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-dofetilide-cimetidine",
      "label": "Dofetilide + cimetidine",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "dofetilide",
          "name": "Dofetilide",
          "id": "dofetilide",
          "class": "Class III Antiarrhythmic"
        },
        {
          "input": "cimetidine",
          "name": "Cimetidine",
          "id": "cimetidine",
          "class": "H2 Blocker"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Dofetilide exposure may rise with Cimetidine",
      "reviewQuestion": "Can you check whether Dofetilide side effects or monitoring needs could increase?",
      "patientSummary": "Dofetilide side-effect risk may increase",
      "patientQuestion": "Can you check whether Dofetilide side effects or monitoring needs could increase?",
      "clinicianSummary": "Dofetilide exposure may rise with Cimetidine",
      "mechanismSummary": "Cimetidine may increase Dofetilide exposure, raising Dofetilide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (50% capacity). Drivers: Cimetidine inhibitor. Affects Dofetilide, Cimetidine.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 4 sources",
      "evidenceStatus": "fda label · 4 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_dofetilide_renal_cation_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_dofetilide_renal_cation_label",
          "title": "Dofetilide prescribing information - renal cation transport contraindications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 4 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=dofetilide,cimetidine&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-dofetilide-cimetidine",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "dofetilide-cimetidine",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-sotalol-hydrochlorothiazide",
      "label": "Sotalol + hydrochlorothiazide",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "sotalol",
          "name": "Sotalol",
          "id": "sotalol",
          "class": "Class III Antiarrhythmic / Beta-Blocker"
        },
        {
          "input": "hydrochlorothiazide",
          "name": "Hydrochlorothiazide",
          "id": "hydrochlorothiazide",
          "class": "Thiazide"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Hydrochlorothiazide exposure may rise with Sotalol",
      "reviewQuestion": "Can you check whether Hydrochlorothiazide side effects or monitoring needs could increase?",
      "patientSummary": "Hydrochlorothiazide side-effect risk may increase",
      "patientQuestion": "Can you check whether Hydrochlorothiazide side effects or monitoring needs could increase?",
      "clinicianSummary": "Hydrochlorothiazide exposure may rise with Sotalol",
      "mechanismSummary": "Sotalol may increase Hydrochlorothiazide exposure, raising Hydrochlorothiazide toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Sotalol prolongs QT; thiazide-associated hypokalemia/hypomagnesemia lowers repolarization reserve.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 1 source",
      "evidenceStatus": "fda label · 1 source · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_sotalol_qt_renal_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_sotalol_qt_renal_label",
          "title": "Sotalol prescribing information - QT prolongation and renal elimination",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 1 source",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=sotalol,hydrochlorothiazide&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-sotalol-hydrochlorothiazide",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "sotalol-hydrochlorothiazide",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-ranolazine-diltiazem",
      "label": "Ranolazine + diltiazem",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ranolazine",
          "name": "Ranolazine",
          "id": "ranolazine",
          "class": "Antianginal / Late Sodium Current Inhibitor"
        },
        {
          "input": "diltiazem",
          "name": "Diltiazem",
          "id": "diltiazem",
          "class": "CCB"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Ranolazine exposure may rise with Diltiazem",
      "reviewQuestion": "Can you check whether Ranolazine side effects or monitoring needs could increase?",
      "patientSummary": "Ranolazine side-effect risk may increase",
      "patientQuestion": "Can you check whether Ranolazine side effects or monitoring needs could increase?",
      "clinicianSummary": "Ranolazine exposure may rise with Diltiazem",
      "mechanismSummary": "Diltiazem may increase Ranolazine exposure, raising Ranolazine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (45% capacity). Drivers: Diltiazem inhibitor, current stack substrate burden. Affects Ranolazine, Diltiazem.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_ranolazine_cyp3a_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_ranolazine_cyp3a_label",
          "title": "Ranolazine prescribing information - CYP3A inhibitors, QT prolongation, and OCT2 substrates",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ranolazine,diltiazem&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-ranolazine-diltiazem",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ranolazine-diltiazem",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-ivabradine-clarithromycin",
      "label": "Ivabradine + clarithromycin",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "ivabradine",
          "name": "Ivabradine",
          "id": "ivabradine",
          "class": "If Current Inhibitor / Heart Rate Lowering Agent"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Slow heart-rate risk may increase",
      "reviewQuestion": "Can you check whether this combination could slow my heart rate or pulse too much?",
      "patientSummary": "Slow heart-rate risk may increase",
      "patientQuestion": "Can you check whether this combination could slow my heart rate or pulse too much?",
      "clinicianSummary": "Slow heart-rate risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Ivabradine, Clarithromycin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_ivabradine_cyp3a_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_ivabradine_cyp3a_label",
          "title": "Ivabradine prescribing information - CYP3A4 inhibitor contraindications",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=ivabradine,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-ivabradine-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "ivabradine-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "cardiology-qt-propafenone-metoprolol",
      "label": "Propafenone + metoprolol",
      "guideId": "cardiology-qt",
      "guideTitle": "QT Risk, Antiarrhythmics, and Rate Control",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "propafenone",
          "name": "Propafenone",
          "id": "propafenone",
          "class": "Class IC Antiarrhythmic"
        },
        {
          "input": "metoprolol",
          "name": "Metoprolol",
          "id": "metoprolol",
          "class": "Beta-blocker"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Low blood pressure risk may increase",
      "reviewQuestion": "Can you check whether my gene result could raise Metoprolol side effects, pulse, blood pressure, or monitoring needs?",
      "patientSummary": "Metoprolol side-effect risk may increase",
      "patientQuestion": "Can you check whether my gene result could raise Metoprolol side effects, pulse, blood pressure, or monitoring needs?",
      "clinicianSummary": "Low blood pressure risk may increase",
      "mechanismSummary": "Pharmacodynamic burden is the shared concern. Pairwise and pathway signals that feed this burden are grouped below.",
      "clinicalRationale": "CYP2D6 genetic phenotype is normal metabolizer; functional phenotype is intermediate function (45% capacity). Drivers: Propafenone inhibitor, current stack substrate burden. Affects Propafenone, Metoprolol.",
      "reviewFocus": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "reviewAction": "Review dose, timing, monitoring, and whether the combination is still appropriate.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_propafenone_cyp2d6_pgx",
        "ev_metoprolol_cyp2d6_cpic"
      ],
      "evidenceSources": [
        {
          "ref": "ev_propafenone_cyp2d6_pgx",
          "title": "Propafenone prescribing information — CYP2D6 substrate, inhibitor, and cardiac drug interactions",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_metoprolol_cyp2d6_cpic",
          "title": "CPIC guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and beta-blocker therapy",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/",
        "https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=propafenone,metoprolol&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#cardiology-qt-propafenone-metoprolol",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "propafenone-metoprolol",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-tacrolimus-fluconazole",
      "label": "Tacrolimus + fluconazole",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "tacrolimus",
          "name": "Tacrolimus",
          "id": "tacrolimus",
          "class": "Immunosuppressant"
        },
        {
          "input": "fluconazole",
          "name": "Fluconazole",
          "id": "fluconazole",
          "class": "Azole Antifungal"
        }
      ],
      "genotypes": [],
      "severity": "moderate",
      "priority": "moderate",
      "summary": "Tacrolimus exposure may rise with Fluconazole",
      "reviewQuestion": "Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?",
      "patientSummary": "Tacrolimus side-effect risk may increase",
      "patientQuestion": "Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?",
      "clinicianSummary": "Tacrolimus exposure may rise with Fluconazole",
      "mechanismSummary": "Fluconazole may increase Tacrolimus exposure, raising Tacrolimus toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP2C9 genetic phenotype is normal metabolizer; functional phenotype is poor function (20% capacity). Drivers: Fluconazole inhibitor.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, monitoring, or specialist/pharmacist input before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 8 sources",
      "evidenceStatus": "guideline · 8 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_tacrolimus_cyp3a5_cpic",
        "ev_tacrolimus_liver_multigene_ladd2025",
        "ev_tacrolimus_renal_dose_model_srinivas2023",
        "ev_tacrolimus_cyp3a5_consensus"
      ],
      "evidenceSources": [
        {
          "ref": "ev_tacrolimus_cyp3a5_cpic",
          "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing",
          "type": "guideline",
          "pmid": "25801146",
          "doi": "10.1002/cpt.113",
          "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_liver_multigene_ladd2025",
          "title": "Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation",
          "type": "clinical_pk",
          "pmid": "40604035",
          "doi": "10.1038/s41598-025-09296-1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40604035/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_renal_dose_model_srinivas2023",
          "title": "Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients",
          "type": "clinical_pk",
          "pmid": "34916931",
          "doi": "10.3389/fphar.2021.726784",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34916931/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_cyp3a5_consensus",
          "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP3A5 Genotype and Tacrolimus Dosing",
          "type": "guideline",
          "pmid": "25813372",
          "doi": "10.1002/cpt.113",
          "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
        "https://pubmed.ncbi.nlm.nih.gov/40604035/",
        "https://pubmed.ncbi.nlm.nih.gov/34916931/",
        "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 8 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=tacrolimus,fluconazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-tacrolimus-fluconazole",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "tacrolimus-fluconazole",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-tacrolimus-clarithromycin",
      "label": "Tacrolimus + clarithromycin",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "tacrolimus",
          "name": "Tacrolimus",
          "id": "tacrolimus",
          "class": "Immunosuppressant"
        },
        {
          "input": "clarithromycin",
          "name": "Clarithromycin",
          "id": "clarithromycin",
          "class": "Macrolide AB"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Tacrolimus exposure may rise with Clarithromycin",
      "reviewQuestion": "Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?",
      "patientSummary": "Tacrolimus side-effect risk may increase",
      "patientQuestion": "Can you check whether this combination could raise Tacrolimus side effects or monitoring needs?",
      "clinicianSummary": "Tacrolimus exposure may rise with Clarithromycin",
      "mechanismSummary": "Clarithromycin may increase Tacrolimus exposure, raising Tacrolimus toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Clarithromycin inhibitor, current stack substrate burden. Affects Tacrolimus, Clarithromycin.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · guideline · 9 sources",
      "evidenceStatus": "guideline · 9 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_transplant_perioperative_workflow",
        "ev_tacrolimus_cyp3a5_consensus",
        "ev_tacrolimus_cyp3a5_cpic",
        "ev_tacrolimus_liver_multigene_ladd2025",
        "ev_tacrolimus_renal_dose_model_srinivas2023"
      ],
      "evidenceSources": [
        {
          "ref": "ev_transplant_perioperative_workflow",
          "title": "Transplant perioperative and immunosuppression medication workflow coverage: induction biologics, calcineurin/mTOR TDM, infection prophylaxis, CMV therapy, live vaccines, and nephrotoxicity",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://kdigo.org/guidelines/transplant-recipient/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_cyp3a5_consensus",
          "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP3A5 Genotype and Tacrolimus Dosing",
          "type": "guideline",
          "pmid": "25813372",
          "doi": "10.1002/cpt.113",
          "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_cyp3a5_cpic",
          "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing",
          "type": "guideline",
          "pmid": "25801146",
          "doi": "10.1002/cpt.113",
          "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_liver_multigene_ladd2025",
          "title": "Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation",
          "type": "clinical_pk",
          "pmid": "40604035",
          "doi": "10.1038/s41598-025-09296-1",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40604035/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_tacrolimus_renal_dose_model_srinivas2023",
          "title": "Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients",
          "type": "clinical_pk",
          "pmid": "34916931",
          "doi": "10.3389/fphar.2021.726784",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34916931/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://kdigo.org/guidelines/transplant-recipient/",
        "https://cpicpgx.org/guidelines/guideline-for-tacrolimus/",
        "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
        "https://pubmed.ncbi.nlm.nih.gov/40604035/",
        "https://pubmed.ncbi.nlm.nih.gov/34916931/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · guideline · 9 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=tacrolimus,clarithromycin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-tacrolimus-clarithromycin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "tacrolimus-clarithromycin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-cyclosporine-posaconazole",
      "label": "Cyclosporine + posaconazole",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "cyclosporine",
          "name": "Cyclosporine",
          "id": "cyclosporine",
          "class": "Immunosuppressant"
        },
        {
          "input": "posaconazole",
          "name": "Posaconazole",
          "id": "posaconazole",
          "class": "Azole Antifungal"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Cyclosporine exposure may rise with Posaconazole",
      "reviewQuestion": "Can you check whether Cyclosporine side effects or monitoring needs could increase?",
      "patientSummary": "Cyclosporine side-effect risk may increase",
      "patientQuestion": "Can you check whether Cyclosporine side effects or monitoring needs could increase?",
      "clinicianSummary": "Cyclosporine exposure may rise with Posaconazole",
      "mechanismSummary": "Posaconazole may increase Cyclosporine exposure, raising Cyclosporine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Posaconazole inhibits CYP3A/P-gp and can increase cyclosporine exposure.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "linked source · guideline · 5 sources",
      "evidenceStatus": "guideline · 5 sources · mechanistic high · linked source",
      "evidenceRefs": [
        "ev_transplant_perioperative_workflow"
      ],
      "evidenceSources": [
        {
          "ref": "ev_transplant_perioperative_workflow",
          "title": "Transplant perioperative and immunosuppression medication workflow coverage: induction biologics, calcineurin/mTOR TDM, infection prophylaxis, CMV therapy, live vaccines, and nephrotoxicity",
          "type": "guideline",
          "pmid": "",
          "doi": "",
          "url": "https://kdigo.org/guidelines/transplant-recipient/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://kdigo.org/guidelines/transplant-recipient/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "linked source · guideline · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=cyclosporine,posaconazole&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-cyclosporine-posaconazole",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "cyclosporine-posaconazole",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-azathioprine-allopurinol-tpmt-nudt15-pm",
      "label": "Azathioprine + allopurinol with TPMT/NUDT15 PM",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "azathioprine",
          "name": "Azathioprine",
          "id": "azathioprine",
          "class": "Immunosuppressant"
        },
        {
          "input": "allopurinol",
          "name": "Allopurinol",
          "id": "allopurinol",
          "class": "XO Inhibitor"
        }
      ],
      "genotypes": [
        "TPMT:PM",
        "NUDT15:PM"
      ],
      "severity": "severe",
      "priority": "severe",
      "summary": "6-Thioguanine nucleotides (6-TGN) may accumulate from Azathioprine",
      "reviewQuestion": "Can you check whether Azathioprine side effects or monitoring needs could increase?",
      "patientSummary": "Azathioprine side-effect risk may increase",
      "patientQuestion": "Can you check whether Azathioprine side effects or monitoring needs could increase?",
      "clinicianSummary": "6-Thioguanine nucleotides (6-TGN) may accumulate from Azathioprine",
      "mechanismSummary": "Allopurinol may increase Azathioprine exposure, raising Azathioprine toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Allopurinol inhibits xanthine oxidase, blocking azathioprine/6-MP metabolism",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 2 sources",
      "evidenceStatus": "fda label · 2 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_allopurinol_azathioprine_xo_label",
        "ev_azathioprine_tpmt_cpic2019"
      ],
      "evidenceSources": [
        {
          "ref": "ev_allopurinol_azathioprine_xo_label",
          "title": "Allopurinol labeling — xanthine oxidase substrate interaction with azathioprine/mercaptopurine",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=allopurinol%20azathioprine",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        },
        {
          "ref": "ev_azathioprine_tpmt_cpic2019",
          "title": "CPIC Guideline for Thiopurines Based on TPMT and NUDT15 Genotype",
          "type": "guideline",
          "pmid": "30447069",
          "doi": "10.1002/cpt.1304",
          "url": "https://pubmed.ncbi.nlm.nih.gov/30447069/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=allopurinol%20azathioprine",
        "https://pubmed.ncbi.nlm.nih.gov/30447069/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=azathioprine,allopurinol&genotype=TPMT:PM&genotype=NUDT15:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-azathioprine-allopurinol-tpmt-nudt15-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "azathioprine-allopurinol-tpmt-nudt15-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-capecitabine-dpyd-pm",
      "label": "Capecitabine with DPYD PM",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "capecitabine",
          "name": "Capecitabine",
          "id": "capecitabine",
          "class": "Chemotherapy"
        }
      ],
      "genotypes": [
        "DPYD:PM"
      ],
      "severity": "severe",
      "priority": "severe",
      "summary": "5-Fluorouracil may accumulate from Capecitabine",
      "reviewQuestion": "Can you check whether Capecitabine side effects or monitoring needs could increase?",
      "patientSummary": "Capecitabine may cause stronger side effects",
      "patientQuestion": "Can you check whether Capecitabine side effects or monitoring needs could increase?",
      "clinicianSummary": "5-Fluorouracil may accumulate from Capecitabine",
      "mechanismSummary": "toxic metabolite accumulation: parent neutral, toxic metabolite up. 5-FU from capecitabine accumulates -> life-threatening toxicity",
      "clinicalRationale": "toxic metabolite accumulation: parent neutral, toxic metabolite up. 5-FU from capecitabine accumulates -> life-threatening toxicity",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "linked source · guideline · 2 sources",
      "evidenceStatus": "guideline · 2 sources · mechanistic high · linked source",
      "evidenceRefs": [
        "ev_fluorouracil_dpyd_amstutz2018"
      ],
      "evidenceSources": [
        {
          "ref": "ev_fluorouracil_dpyd_amstutz2018",
          "title": "CPIC Guideline for Fluoropyrimidines and DPYD Genotype",
          "type": "guideline",
          "pmid": "29152729",
          "doi": "10.1002/cpt.911",
          "url": "https://pubmed.ncbi.nlm.nih.gov/29152729/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/29152729/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "linked source · guideline · 2 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=capecitabine&genotype=DPYD:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-capecitabine-dpyd-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "capecitabine-dpyd-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-irinotecan-ugt1a1-pm",
      "label": "Irinotecan with UGT1A1 PM",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_or_pgx_example",
      "substances": [
        {
          "input": "irinotecan",
          "name": "Irinotecan",
          "id": "irinotecan",
          "class": "Chemotherapy"
        }
      ],
      "genotypes": [
        "UGT1A1:PM"
      ],
      "severity": "severe",
      "priority": "severe",
      "summary": "SN-38 may accumulate from Irinotecan",
      "reviewQuestion": "Can you check whether Irinotecan side effects or monitoring needs could increase?",
      "patientSummary": "Irinotecan may cause stronger side effects",
      "patientQuestion": "Can you check whether Irinotecan side effects or monitoring needs could increase?",
      "clinicianSummary": "SN-38 may accumulate from Irinotecan",
      "mechanismSummary": "toxic metabolite accumulation: parent neutral, toxic metabolite up. SN-38 exposure higher; reduce starting dose and monitor CBC",
      "clinicalRationale": "toxic metabolite accumulation: parent neutral, toxic metabolite up. SN-38 exposure higher; reduce starting dose and monitor CBC",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "primary-literature linked · guideline · 6 sources",
      "evidenceStatus": "guideline · 6 sources · mechanistic high · primary-literature linked",
      "evidenceRefs": [
        "ev_irinotecan_ugt1a1_ramsey2014",
        "ev_irinotecan_ugt1a1_stewart2007",
        "ev_irinotecan_ugt1a_han2006",
        "ev_irinotecan_sn38_review_mathijssen2001"
      ],
      "evidenceSources": [
        {
          "ref": "ev_irinotecan_ugt1a1_ramsey2014",
          "title": "CPIC Guideline for Irinotecan Therapy Based on UGT1A1 Genotype",
          "type": "guideline",
          "pmid": "24786769",
          "doi": "10.1038/clpt.2014.21",
          "url": "https://pubmed.ncbi.nlm.nih.gov/24786769/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        },
        {
          "ref": "ev_irinotecan_ugt1a1_stewart2007",
          "title": "UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan",
          "type": "clinical_pk",
          "pmid": "17577039",
          "doi": "10.1200/jco.2006.10.2301",
          "url": "https://pubmed.ncbi.nlm.nih.gov/17577039/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_irinotecan_ugt1a_han2006",
          "title": "Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in irinotecan/cisplatin",
          "type": "clinical_pk",
          "pmid": "16636344",
          "doi": "10.1200/jco.2005.03.0239",
          "url": "https://pubmed.ncbi.nlm.nih.gov/16636344/",
          "public": true,
          "modeled": false,
          "provenance": "primary_literature",
          "directUrl": true
        },
        {
          "ref": "ev_irinotecan_sn38_review_mathijssen2001",
          "title": "Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)",
          "type": "review",
          "pmid": "11489791",
          "doi": "",
          "url": "https://pubmed.ncbi.nlm.nih.gov/11489791/",
          "public": true,
          "modeled": false,
          "provenance": "linked_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://pubmed.ncbi.nlm.nih.gov/24786769/",
        "https://pubmed.ncbi.nlm.nih.gov/17577039/",
        "https://pubmed.ncbi.nlm.nih.gov/16636344/",
        "https://pubmed.ncbi.nlm.nih.gov/11489791/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "primary-literature linked · guideline · 6 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=irinotecan&genotype=UGT1A1:PM&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-irinotecan-ugt1a1-pm",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "irinotecan-ugt1a1-pm",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-venetoclax-ritonavir",
      "label": "Venetoclax + ritonavir",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "venetoclax",
          "name": "Venetoclax",
          "id": "venetoclax",
          "class": "BCL-2 Inhibitor"
        },
        {
          "input": "ritonavir",
          "name": "Ritonavir",
          "id": "ritonavir",
          "class": "Protease Inhibitor"
        }
      ],
      "genotypes": [],
      "severity": "critical",
      "priority": "critical",
      "summary": "Venetoclax exposure may rise with Ritonavir",
      "reviewQuestion": "Can you check whether Venetoclax side effects or monitoring needs could increase?",
      "patientSummary": "Venetoclax side-effect risk may increase",
      "patientQuestion": "Can you check whether Venetoclax side effects or monitoring needs could increase?",
      "clinicianSummary": "Venetoclax exposure may rise with Ritonavir",
      "mechanismSummary": "Ritonavir may increase Venetoclax exposure, raising Venetoclax toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "CYP3A4 genetic phenotype is normal metabolizer; functional phenotype is poor function (18% capacity). Drivers: Ritonavir inhibitor, current stack substrate burden. Affects Venetoclax, Ritonavir.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 5 sources",
      "evidenceStatus": "fda label · 5 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_venetoclax_cyp3a_pgp_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_venetoclax_cyp3a_pgp_label",
          "title": "Venetoclax prescribing information - CYP3A/P-gp inhibitors and strong inducers",
          "type": "fda_label",
          "pmid": "",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 5 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=venetoclax,ritonavir&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-venetoclax-ritonavir",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "venetoclax-ritonavir",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    },
    {
      "schema": "diognosis.reference-fact.v1",
      "id": "oncology-transplant-erlotinib-rifampin",
      "label": "Erlotinib + rifampin",
      "guideId": "oncology-transplant",
      "guideTitle": "Oncology, Immunology, and Transplant",
      "factType": "interaction_example",
      "substances": [
        {
          "input": "erlotinib",
          "name": "Erlotinib",
          "id": "erlotinib",
          "class": "EGFR Tyrosine Kinase Inhibitor"
        },
        {
          "input": "rifampin",
          "name": "Rifampin",
          "id": "rifampin",
          "class": "Rifamycin"
        }
      ],
      "genotypes": [],
      "severity": "severe",
      "priority": "severe",
      "summary": "Erlotinib exposure may rise with Rifampin",
      "reviewQuestion": "Can you check whether Erlotinib side effects or monitoring needs could increase?",
      "patientSummary": "Erlotinib may work less well",
      "patientQuestion": "Can you check whether Erlotinib side effects or monitoring needs could increase?",
      "clinicianSummary": "Erlotinib exposure may rise with Rifampin",
      "mechanismSummary": "Rifampin may increase Erlotinib exposure, raising Erlotinib toxicity review priority. Related pathway, metabolite, and evidence signals are grouped below.",
      "clinicalRationale": "Rifampin induces CYP3A4 and CYP1A2, reducing erlotinib AUC by ~66%.",
      "reviewFocus": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "reviewAction": "Review whether this combination needs a different plan, dose context, timing, or monitoring before any medication changes.",
      "evidenceSummary": "authority-linked · fda label · 3 sources",
      "evidenceStatus": "fda label · 3 sources · mechanistic high · authority-linked",
      "evidenceRefs": [
        "ev_erlotinib_cyp3a_label"
      ],
      "evidenceSources": [
        {
          "ref": "ev_erlotinib_cyp3a_label",
          "title": "Erlotinib (Tarceva) prescribing information — CYP3A4/CYP1A2 metabolism and smoking interaction",
          "type": "fda_label",
          "pmid": "16203810",
          "doi": "",
          "url": "https://dailymed.nlm.nih.gov/dailymed/",
          "public": true,
          "modeled": false,
          "provenance": "authority_source",
          "directUrl": true
        }
      ],
      "sourceUrls": [
        "https://dailymed.nlm.nih.gov/dailymed/"
      ],
      "sourceLinked": true,
      "provenanceStatus": "authority-linked · fda label · 3 sources",
      "independentReviewStatus": "not_independently_reviewed",
      "sourceIntegrationStatus": "not_independently_reviewed",
      "sourceIntegrated": true,
      "boundary": "Educational medication-safety reference only. Not medical advice, not a clinical decision support system, and not clinical validation. Do not start, stop, or change medicines without a qualified doctor or pharmacist.",
      "appUrl": "https://diogonmpacheco.github.io/Diognosis/index.html#substances=erlotinib,rifampin&tab=overview",
      "referenceUrl": "https://diogonmpacheco.github.io/Diognosis/reference/index.html#oncology-transplant-erlotinib-rifampin",
      "generatedFrom": {
        "source": "data/medication-class-guides.json",
        "exampleId": "erlotinib-rifampin",
        "validation": "data-resolved"
      },
      "version": {
        "engine": "0.1.0-alpha.1",
        "drugDb": "1.2.3",
        "schema": "graph-v1",
        "released": "2026-06-10"
      },
      "generatedAt": "2026-07-11T05:35:41.222Z",
      "lastmod": "2026-07-11"
    }
  ]
}
